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The microtubule associate protein tau, in a hyperphosphorylated form, loses 
its normal function and aggregates into insoluble paired-helical filaments (PHFs) in 
Alzheimer’s disease (AD) and other tauopathies.  The stoichiometry of 
phosphorylation is increased from 2-3 mol of phosphate per mole of tau in normal 
brain to 5-9 mol of phosphate per mole of tau in AD.  In AD, the deregulation of 
kinases, such as glycogen synthase kinase-3β (GSK-3β), is believed to be associated 
with the generation of hyperphosphorylated tau.  However, the functional 
contribution of hyperphosphorylation on AD is not well understood.  Therefore, 
pseudohyperphosphorylation mutants at six or sever GSK-3β phosphorylation sites 
were generated by amino acid substitution.  In addition, several single, double and 
triple pseudophosphorylation mutants at these sites were also generated and used as 
controls.  I studied the changes on mobility on SDS-PAGE, microtubule (MT) 
binding and arachidonic acid (ARA) induced polymerization.  Four 
pseudophosphorylation mutants induced an SDS-resistant mobility change.  All but 
three mutants had a reduced MT binding affinity and pseudohyperphosphorylation 
mutants did not have a greater effect compared with pseudophosphorylation mutants 
at single or double sites.  Three pseudohyperphosphorylation mutants with retarded 
SDS mobility had a greater effect on ARA-induced polymerization, with reduced 
nucleation and elongation rate.  Some pseudophosphorylation mutants had a 
significantly increased polymerization at high ARA concentrations compared with 
wild type tau.  The tangle like aggregates similar to those isolated from AD brain 
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were formed in the mixture of six pseudophosphorylation mutants.  These 
observations suggest the increased toxicity of hyperphosphorylated tau may be 
induced by decreased MT binding affinity and reduced nucleation and 
polymerization rate.  These observations also explain the potentially beneficial role 
of tau polymerization and NFT formation. 
I also studied the mechanism of ARA-induced tau polymerization.  The 
results suggest that ARA can induce tau polymerization both as large micelles and 
monomers (or small micelles) and molecular nature of tau can affect the morphology 
of tau filament.  The amount and morphology of tau filament can also be affected by 
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CHAPTER 1 INTRODUCTION 
  In 1975, Tau protein was first isolated by Weingarten and colleagues as a 
protein factor that co-purified with tubulin and was able to promote microtubule 
assembly (1, 2).  About ten years later, tau was found to be the major component of 
neurofibrillary tangles (NFTs), one of the hallmarks of Alzheimer’s disease (AD), by 
several groups (3-7).   This finding evoked new interest in the study of tau protein. 
 
1.1 The structure and function of human tau in normal neurons 
In human brain, there are six different isoforms of tau protein, which are all 
translated from a single gene on chromosome 17 at position 17q21, named MAPT (8, 
9).  The MAPT gene contains 16 exons and the alternative splicing of exon 2, 3 and 
10 results in the generation of 6 tau isoforms, ranging from 352 to 441 amino acids 
(Figure 1.1)(reviewed in (8)).  These isoforms differ by the presence of 3 or 4 
microtubule binding repeats combined with the presence of 0, 1 or 2 N-terminal 
insertions (reviewed in (8)).  The additional microtubule binding repeat R2 is encoded 
by exon 10 and the two N-terminal insertions are encoded by exon 2 and exon 3 
(Figure 1.1).  These tau isoforms are named ht23 (0N3R), ht24 (0N4R), ht34 (1N4R), 
ht37 (1N3R), ht39 (2N3R), and ht40 (2N4R), where N represents the N-terminal 
insertions and R represents the microtubule binding repeats (10, 11).  Human tau 
protein mainly locates in neurons with high concentrations of tau observed in axons.  
The expression of these tau isoforms is developmentally regulated, with ht23 (0N3R) 
being the only isoform present in fetal brain (also called fetal tau) and all six isoforms 
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being present in adult brain (reviewed in (8)).  Furthermore, there are about equal 
amounts of 3R and 4R isoforms in adult brain (12).   
The major functions of tau are to bind and stabilize microtubules and to 
promote microtubule assembly.  The C-terminal part of tau binds to microtubules 
(reviewed in (8)), and is named the microtubule binding domain (Figure 1.2).  The 
microtubule binding domain has 3 or 4 microtubule binding repeats (R1 – R4), which 
are encoded by exons 9-12.  These microtubule binding repeats and the regions in 
between these repeats contribute to the binding between tau and microtubules 
(reviewed in (13)).  The 4R isoforms have a higher binding affinity compared with 
3R isoforms due to the presence of an additional binding repeat and strong 
interactions between microtubules and the internal regions between R1 and R2 
(reviewed in (8)).   The proline-rich region also contributes to the binding between 
tau and microtubules (14).   
The rest of the tau protein, the projection domain, projects from the surface of 
the microtubules.  This domain includes the N-terminal part of the protein and the 
following proline-rich region (Figure 1.2).  The major function of the projection 
domain is to control the spacing between microtubules in the axon (15), therefore 
controlling the diameter of the axon (reviewed in  (8)).  Tau has other functions in 
cells including interactions with cytoskeleton components (actins and neurofilaments), 
cytoplasmic organelles, the plasma membrane and regulatory functions during 
development (reviewed in  (8, 16)). 
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Figure 1.1.  Schematic representation of human tau gene and the six tau isoforms found 
in human central nervous system (CNS).  Human tau gene is located on chromosome 17 at 
position 17q21 and contains 16 exons.  Exon 1 is a part of the promoter.  Exon 4A, 6 and 8 
are not transcribed in human CNS.  Alternative splicing of exon 2, 3 and 10 produces the six 
tau isoforms in human brain.  These isoforms differ by the absence or presence of one or two 
N-terminal 29 amino acids inserts (dark gray box), encoded by exon 2 and 3, in combination 
with three or four 18 amino acid microtubule binding repeats (black box and light gray box, 



















Figure 1.2.  Schematic representation of the functional domains on the longest human 
tau isoform (2N4R).  The microtubule binding domain is the C-terminal part of the protein 
and contains four microtubule-binding repeats.  The function of this domain is to bind and 
stabilize microtubules.  The projection domain contains N-terminal acidic region and the 
following proline-rich region.  This domain interacts with cytoskeletal elements and 











Tau loses its normal functions in some neurodegenerative diseases and 
aggregates into insoluble paired helical filaments (PHFs), straight filaments (SFs) and 
neurofibrillary tangles (NFTs) (reviewed in (8)).  The neurodegenerative diseases 
include: Alzheimer’s disease (AD), Pick’s disease (PiD), progressive supranuclear 
palsy (PSP), corticobasal degeneration (CBD) and frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17).   
 
1.2 Alzheimer’s Disease and tauopathies 
1.2.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) was first described by Dr. Alois Alzheimer in 1906.  
AD is a progressive dementia characterized by the presence of amyloid plaques and 
neurofibrillary tangles (reviewed in  (8)). AD is the most common form of dementia 
and accounting up to 50 - 70 percent of all dementia cases (http://www.alz.org).    
There were approximately 18 million AD patients worldwide by 2007.  Today, in the 
US, as many as 5.3 million people are living with AD and AD is the 6th-leading cause 
of death in the US (http://www.alz.org).  In a conservative estimation, 1 in 10 of those 
over 65 and 1 in 5 of those over 85 years old are likely to have AD (reviewed in (17)).  
With the extension of the average life span, we are facing an increasing number of 
AD cases.   
With the progression of AD, some pathological changes occur in the brain.  
These include, but are not limited to, reduced brain size, neuronal loss, the presence 
of amyloid plaques and the presence of neurofibrillary tangles.  Among these 
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pathological changes, amyloid plaques and neurofibrillary tangles are the two most 
prominent and are used as the diagnostic hallmarks of AD (reviewed in (17)).   
The major component of amyloid plaques is β amyloid peptide (Aβ), which 
homogenously distributes in the plaques (reviewed in (17)).   
The second most distinctive pathological component of AD is neurofibrillary 
tangles (NFTs).  NFTs are mainly found in the cortex and hippocampus (18).  Most 
NFTs are intracellular, although some extracellular “ghost tangles” are also present in 
AD brain.  These “ghost tangles” are the insoluble components of dead neurons 
(reviewed in (17)). The number and distribution of NFTs relate to the type and degree 
of dementia, and the spreading of NFTs has been used as a diagnostic sign of the 
stage of the dementia (19).   NFTs are Thioflavine S (ThS) positive and tau is the 
major component of NFTs.  Tau protein isolated from NFTs is abnormally 
hyperphosphorylated and is in the form of insoluble paired helical filaments (PHFs) 
and straight filaments (SFs) (20, 21).  PHFs are the wound helices of a pair of 
unbranched filaments.  PHFs are approximately 20 nm across and 80 nm long per 
period.   SFs are filaments with a width between 5 - 20 nm, with no periodical 
changes in the width.  Both PHFs and SFs in AD contain all six isoforms of tau 
(reviewed (17)).  In addition to tau, other components are found in NFTs, including 
ubiquitin (22), RNA (23), α-synuclein (24), GSK-3β (25) and apolipoprotein E (26).  
In AD, tau pathology was found to be associated with Aβ pathology in neuritic 
plaques.  Aβ peptides are in the center of neuritic plaques.  Other components, such as 
apolipoprotein E and amyloid precursor protein, form a less condensed halo around 
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the plaques (reviewed in (17)).  Tau, in the form of insoluble paired helical filaments 
(PHF), is also found to be present in the halo (27). 
Neuron loss is also observed in AD.  There is as high as a 70% reduction in 
the number of neurons in AD (reviewed in (17)).  Most of these neurons are the 
neurons prone to NFT formation, such as the disrupted neurons that result in “ghost 
tangles” (28, 29).  Also, the shrinkage of the remaining neurons happens frequently in 
AD (28).  Besides the changes to neuronal cells, abnormal glial cells are observed in 
AD.  The activated glial cells, mainly astrocytes and microglial cells, are found in AD 
brains (reviewed in (17)).   
 
1.2.2 Other tauopathies 
Alzheimer’s disease is associated with both extracellular Aβ deposits and 
intracellular NFTs.  Therefore, it has been questioned whether the changes in tau 
function contribute to dementia or are a non-specific event associated with Aβ 
deposits.  The finding of pathological tau deposits in a group of neurodegenerative 
diseases in which Aβ deposits are totally or mostly absent, suggests that the changes 
in tau function alone is sufficient to cause neurodegenerative diseases.  Tau deposits 
in these diseases are different in morphology and the percentage of each isoform (see 
below).  These diseases include: Pick’s disease (PiD), progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD) and frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17).  These diseases are collectively 
termed tauopathies (reviewed in (30)).   
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1.2.2.1 Pick’s Disease (PiD) 
PiD is a neurodegenerative disease characterized by the presence of Pick 
bodies.  Pick bodies are intracellular, anti-PHFs-tau antibody positive inclusions in 
brains (reviewed in (30)).  Close examination of  Pick bodies showed that tau in Pick 
bodies is a mix of straight filaments (SFs) and twisted ribbon filaments with long-
periods (31).  Tau isolated from Pick bodies is also abnormally hyperphosphorylated, 
similar to tau isolated from AD (reviewed in (30)). 
 
1.2.2.2 Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) 
In PSP and CBD, tau deposits form in both neurons and glial cells.  
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are late 
onset, neurodegenerative diseases with neuronal loss and NFT formation in neurons 
and glial cells (reviewed in (13)).  The major component of NFTs is 
hyperphosphorylated tau protein but in different forms in PSP and CBD.  In PSP, 
straight filaments are the major forms of tau in NFTs, and twisted ribbons with a long 
period are also observed in tangles (reviewed in  (8)).  In CBD, tau filaments are in 
the form of paired helical filaments (PHFs) and straight filaments (SFs) (reviewed in 
(13)).  
 
1.2.2.3 Frontotemporal dementia with Parkinsonism linked to chromosome 17 
(FTDP-17) 
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Although tau positive inclusions are found in these tauopathies, they were first 
thought of as a non-specific event accompanying neurodegeneration.  The causative 
role of tau in AD was bolstered by the discovery of mutations in the tau gene in 
inherited FTDP-17, which are autosomal dominant, adult-onset, neurodegenerative 
disorders (32).  Because similar changes in tau function and neuropathologies were 
observed in FTDP-17 as in AD and other tauopathies, studies on these FTDP-17 
mutations contribute to the understanding of the role of tau protein in non-familial 
tauopathies. 
To date, 38 mutations of the tau (MAPT) gene have been identified from 
studies of over 100 families with FTDP-17 (Figure 1.3) (32).  The pathologies vary 
within and between different families with the same or different mutations (reviewed 
in (33)).  The formation of tau deposits in neurons and/or glial cells is one of the 
major characteristics of FTDP-17 ((reviewed in (34)).  Other general characteristics 
include neuronal atrophy, neuronal loss and active glial cell (reviewed in (33)).  The 
neuropathology may resemble that of AD or PiD because of the presence of NFTs in 
neurons or resemble those of PSP or CBD because of tau deposits in glial cells 
(reviewed in (33)).  Usually little or no amyloid deposition is observed in FTDP-17.  
Most of the FTDP-17 mutations are in the coding region of tau (Figure 1.3).  All of 
the exonal mutations are located in the MT-binding region (exons 9-12) or close to it, 
with R5H/L to be the only exception.  The rest of the mutations (E9+33, +3, +11, +12, 
+13, +14, +16, +19, +29) occur in the introns downstream of exon 9 and exon 10, 







Figure 1.3. Schematic representation of mutations in human MAPT gene associated with 
FTDP-17.  FTDP-17 mutations are listed in the figure and labeled with red.  The mutations 
on the pre-mRNA stem-loop and the downstream intron are shown in the insertion.  The 
mutations in this region affect the splicing of the gene.  Exonic sequences are labeled with 
uppercase letters and intronic sequences in lowercase.  The relative sizes of the exons are not 





All these mutations can be classified into three groups: mutations altering the 
tau-microtubule interactions; mutations altering tau mRNA splicing; and mutations 
altering both tau-microtubule interactions and tau RNA splicing.  The mutants in the 
first group, such as P301L and P301S decrease the binding affinity of tau to 
microtubules and/or reduce their ability to promote microtubule assembly (32).   Most 
of the mutants with reduced tau-microtubule interactions also more readily 
aggregated into filaments (35).  The second group is the mutations that alter tau 
mRNA splicing.  This group includes all of the mutations in the intron downstream of 
exon 10 and most of the coding mutations in exon 10 (36).  Several deletion and 
missense mutations in exon 10 affect both the splicing of mRNA and tau protein 
function, and belong to the third group.  These mutations are DelK280, N296H and 
S305N (8, 13, 30, 32-34). 
The link between tau mutations and FTDP-17 phenotypes emphasizes that tau 
dysfunction itself can cause neurodegenerative disorders.  The reduced microtubule 
binding activity and the subsequent aggregation are key events in the progression of 
neurodegeneration. 
 
1.3 Pathological tau deposits: 
The presence of tau deposits in AD and other tauopathies is one of the 
prominent characteristics of these neurodegenerative diseases.  However, the tau 
deposits in different tauopathies are different not only in the ultrastructure of the 
deposits, but the percentage of each isoform (reviewed in (13)).   
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In AD and some of the FTDP-17 resembling AD, such as tau mutants L266V, 
L315R, S320F, V337M, K369I, R406W (reviewed in (32, 37)), a small number of 
SFs and a large number of PHFs are present and all six brain tau isoforms can be 
isolated from the tau deposits (reviewed in (13)).  The core of a PHF is composed of 
the microtubule binding region of tau (38).  When separation by SDS-PAGE, tau in 
PHFs and SFs from AD is present in three major bands (68, 64 and 60 kDa) and a 
minor band at 72kDa (Figure 1.4) and all tau is hyperphosphorylated (39, 40).  When 
de-phosphorylated by alkaline phosphatase, the four bands resolve into six bands 
corresponding to the six isoforms (Figure 1.4) (41, 42). 
In PiD and some of the FTDP-17 mutations (i.e. K257T, G272V, DelK280 
and G389R), twisted ribbons and SFs are the major forms of insoluble tau and only 
3R isoforms are present in the tau deposits.  SDS-PAGE analysis of the insoluble tau 
reveals two major bands (64 kDa and 60 kDa) and a minor band (68 kDa), and all of 
which are hyperphosphorylated (Figure 1.4) (reviewed in (13)).  Dephosphorylation 
of the insoluble tau results in 3 bands corresponding to the three 3R isoforms (Figure 
1.4).  However, all six brain isoforms are expressed and found in soluble components 
in brain (reviewed in (32, 37)). 
Another pattern of the insoluble tau is seen in CBD, PSP and some FTDP-17 
(such as R5H/L, I260V, N279K, N296H/N, P301L, E342V, +3, +12, +13, +14 and 
+16) (reviewed in (13)).  In these cases, tau deposits are in the form of twisted 
ribbons and SFs, and only hyperphosphorylated 4R isoforms are found in the deposits 















Figure 1.4. Schematic representation of western blot patterns of insoluble tau bands in 
AD and different tauopathies.  The diagram describes the typical patterns of the insoluble 
tau deposits on SDS-PAGE in AD and various tauopathies.  The sarkosyl-insoluble tau is 
separated by SDS-PAGE and immunoblotted with anti-tau antibodies before (-) and after (+) 
dephosphorylation.  The molecular weights of the bands are labeled on the left and the 
different tau isoforms on the right.  The 1st, 2nd and 3rd pattern of tau bands are mainly found 
in AD, PiD, and CBD and PSP, respectively.  The patterns of FTDP-17 mutations differ 





68 kDa and 64 kDa and a minor band at 72 kDa (Figure 1.4).  The dephosphorylated 
samples resolve into 3 bands corresponding to the three 4R isoforms.  However, the 
expression patterns of tau in CBD, PSP and the FTDP-17 mutants are different.   In 
CBD and PSP, all six isoforms are expressed in the patients’ brains.  In the FTDP-17 
mutations, the expression levels of the 4R isoforms are much higher than those of the 
3R isoforms, due to the changes in mRNA splicing in  these FTDP-17 mutants 
(reviewed in (32, 37)).   
One thing that should be mentioned about the tau deposits is that it is not clear 
if these tau deposits are neurotoxic or neuroprotective.  Evidence from cell models 
and animal models supports the idea that NFTs are neuroprotective (see below). 
 
1.4 Phosphorylation of tau 
A distinct feature of tau isolated from pathological tau deposits in AD and 
tauopathies is that it is abnormally hyperphosphorylated.  The hyperphosphorylated 
tau has similar changes in MT binding and self-aggregation as observed in FTDP-17 
mutations.  Therefore, hyperphosphorylation has been suggested as an early event in 
the progression of AD and tauopathies.  The phosphorylation of tau was also 
observed in normal brain and its function is to regulate tau function. 
There are 85 potential phosphorylation sites on the longest tau isoform.  These 
include 79 serine or threonine sites and 6 tyrosine sites.  Currently, 71 of these 85 
potential sites have been shown to be phosphorylated in physiological or pathological 
conditions.  Most of these sites locate in the proline-rich region and C-terminal region 
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outside of the microtubule binding repeats.  These sites are Thr17, Try18, Try29, 
Thr39, Ser46, Thr50, Thr52, Ser56, Ser68, Thr69, Thr71, Thr95, Thr101, Thr102, 
Thr113, Thr123, Thr131, Thr149, Thr153, Thr169, Thr175, Thr181, Ser184, Ser191, 
Try197, Ser198, Ser199, Ser202, Thr205, Ser208, Ser210, Thr212, Thr214, Ser217, 
Thr220, Ser231, Thr235, Ser237, Ser238, Ser241, Ser245, Ser258, Ser262, Ser263, 
Ser285, Ser289, Ser293, Ser305, Ser316, Ser320, Ser324, Ser341, Ser352, Ser356, 
Thr361, Thr373, Thr386, Try394, Ser396, Ser400, Thr403, Ser404, Ser409, Ser412, 
Ser413, Thr414, Ser416, Ser422, Thr427, Ser433 and Ser435.   
 
1.4.1 Phosphorylation regulates tau function under physiological conditions 
Tau is phosphorylated to 2-3 mol of phosphate per mole of tau in normal brain and 
phosphorylation of tau regulates its function, such as microtubule binding and cell 
sorting (8, 43).  At least 30 sites have been reported to be phosphorylated on normal 
tau (reviewed in (8)).  Stabilizing microtubules and promoting the assembly of 
microtubules are the major functions of tau in neurons.  Phosphorylation of tau can 
negatively regulate tau-microtubule binding affinity as well as its ability to promote 
tubulin assembly (44-46).  The phosphorylation of tau at the sites outside of MT-
binding repeats decreases tau-MT binding in a 2-3 fold range (47).  Phosphorylation 
at the sites inside MT-binding repeats, for example S262, drastically reduces tau-MT 
binding.  However, none of these phosphorylation sites alone is sufficient to totally 
abolish the binding between tau and MTs (48).  The phosphorylation at certain sites 
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could reduce the ability of tau to stimulate tubulin assembly without drastically 
changing the binding affinity between tau and microtubules (49-51). 
The phosphorylation level changes in different developmental stages.  In fetal 
brain, tau is phosphorylated in a higher stoichiometry but not as high as in AD (8, 52, 
53).  The mechanism of transient hyperphosphorylation during development is not 
clear.  The transient hyperphosphorylation may relate to the higher concentration of 
tubulins and higher degree of plasticity of microtubules required during neuron 
development in fetal brain (54).  The concentration of tubulin in fetal brain is about 
1.5 times higher than that in adult brain and the presence of hyperphosphorylated tau 
may reduce the chance of MT bundling (53).  The de-phosphorylation of 
hyperphosphorylated fetal tau is most likely due to the increase of phosphatase 
activation when maturity (8, 52, 53).   
 
1.4.2 Pathological phosphorylation of tau 
Phosphorylation of tau happens under both physiological and pathological 
conditions.  However, the stoichiometries of phosphorylation are different under these 
two conditions.  In AD brain, the stoichiometry of phosphorylation is drastically 
increased from 2-3 mol phosphate per mole of tau in normal brain to 5-9 mol (55).  
Hyperphosphorylated tau is the major component of PHFs, SFs and NFTs, and 
phosphorylation is considered one of the trigger events of AD and tauopathies.  
Hyperphosphorylated tau is also found in the cytosol from AD brain (55).  In AD 
brain, the expression level and the concentration of normal tau are as high as the 
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concentration in age-matched control (56).  However, in addition to the normal tau, 
the concentration of abnormally hyperphosphorylated tau is several fold higher than 
normal tau (55).   
Tau protein in AD and tauopathies is not only hyperphosphorylated but also 
abnormally phosphorylated.  About 45 sites have been found to be phosphorylated in 
PHF tau (Figure 1.5) (53, 57).  Most of these phosphorylation sites cluster in the 
proline-rich region and C-terminal region (53, 57).  The hyperphosphorylation and 
abnormal phosphorylation of pathological tau were first suggested by the following 
findings.  First, the results of 2D gel electrophoresis showed PHF tau was more acidic 
than normal tau.  This increase in acidity was due to the hyperphosphorylation (58).  
Second, the increased phosphorylation levels were all confirmed by the upward band 
shift on the SDS-PAGE exclusively in pathological tau.  Third, by using mass 
spectrometry and antibodies to PHF-tau, pathological tau was found to be 
hyperphosphorylated at both native phosphorylation sites and abnormal pathological 
sites.  Antibodies to PHF-tau, such as AT100 and TG3, can react with tau isolated 
from AD patients but not normal tau (59, 60).   
 
 
1.4.3 Tau phosphorylation and tau aggregation 
Because hyperphosphorylated tau is found in insoluble and cytosolic forms 
from the brains of AD and other tauopathy patients, hyperphosphorylation is 
considered an early event in the development of NFTs.  This idea is supported by the 




Figure 1.5.  Schematic representation of phosphorylation sites on the longest tau 
isoform from AD.  Approximately 45 phosphorylation sites have been identified on PHF tau 
from AD by phosphorylation-specific antibodies and mass spectrometry.  Most of these sites 
cluster in the proline-rich region (light blue box) and C-terminal region.  Black boxes 
represent microtubule binding repeats (R1- R4) and gray boxes represent N-terminal inserts.  








PHFs and SFs under physiological conditions (61).  The dephosphorylation with 
PP2A alone is enough to inhibit the self-aggregation of AD tau (62).  Recent results 
showed that re-phosphorylation of PP2A de-phosphorylated AD tau with several 
combinations of kinases can restore the ability of tau to self-aggregate (63).   
How hyperphosphorylation leads to the formation of filaments and NFTs is not clear.  
It may come from the following changes. First, the hyperphosphorylated tau has a 
lower affinity for MT (63).  Because it is released from MT, the concentration of 
soluble cytosolic tau is drastically increased and this is a more favorable condition for 
tau self-polymerization.  Second, the conformational changes induced by 
phosphorylation make phosphorylated tau a better substrate of kinases and further 
increase its tendency for self-aggregation. Similarly, all known FTDP-17 mutations 
can alter their conformations to the more favorable ones for the interaction with 
kinases and more readily for self-aggregation (64).  Third, the abnormal 
hyperphosphorylation of tau can neutralize inhibitory factors of tau.  Although tau is a 
natively unfolded protein, β-sheet fragments form in its microtubule-binding repeats 
(65).  R3 in 3R isoforms and R2 and R3 in 4R isoforms can self-aggregate because of 
the presence of these β-structures (65).  However, there are negatively charged or 
positively charged amino acids clusters in tau (Figure 1.6).  Because of the positions 
where these charged regions are located, the hydrophobic interactions between tau are 
inhibited and this makes it impossible for normal tau to self-aggregate.  The 
inhibitory effects of these structural elements on tau self-aggregation have been 
confirmed by studies on in vitro tau aggregation (see below).  The phosphorylation 
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sites of tau mainly cluster in the proline rich region and C-terminal region and the 
phosphorylation in these two parts can promote tau self-aggregation by removing 
these inhibitory factors.  In Figure 1.6, a mechanism hypothesized by K. Iqbal 
explains how phosphorylation removes inhibitory factors for tau aggregation (53).  
The charge distributions on tau protein are demonstrated by the calculated different 
isoelectric points (pIs) in different parts.  The proline rich region locates in the N-
terminal side of the MT-binding repeats and is a very basic fragment with pI > 9.  At 
the same time, the presence of proline residues bends the protein and masks the 
intermolecular attractions between microtubule binding repeats.   Phosphorylation in 
the proline-rich region can neutralize the basic charges in this region and remove the 
inhibitory effect (Figure 1.6).  The C-terminal part after Pro-397 is highly acidic.  
This part has been shown to inhibit the self-aggregation of tau (66).  One hypothesis 
for the inhibitory effect of the C-terminal part is that it can mask the region that is 
required for tau- tau interactions (64).  The phosphorylation of S396 and/or S404 can 
open up this    region and allow the interactions between microtubule repeats (Figure 
1.6).  This hypothesis is supported by the increased polymerization rate of the 
S396/S404E pseudophosphorylation mutant (67).   
The fact that hyperphosphorylation can promote tau self-aggregation 
demonstrates AD and tauopathies have impaired phosphorylation and de-
phosphorylation processes.  Therefore, it is of great interest to determine the kinases 
and phosphatases involved in tau phosphorylation/dephosphorylation and their roles 




Figure 1.6.  Schematic representation of a hypothesis of hyperphosphorylation induced 
tau self-aggregation.  The calculated pIs for different regions of the longest tau isoform are 
labeled with different colors.  In normal tau, the highly positively charged proline-rich region 
in the N-terminal side of the microtubule binding repeats inhibits intermolecular attractions 
through R2 and R3.  The phosphorylation in this region due to increased kinase activities 
and/or decreased phosphatase activities neutralizes the positive charges and promotes tau 
self-aggregation.  The C-terminus of tau inhibits tau-tau interaction by masking R2 and R3 
regions.  The phosphorylation at S396 and/or S404 removes the mask and facilitates filament 
formation.  The boxes representing each region are not drawn to scale.  Modified from Iqbal 
et al., 2009. 
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1.4.4 Tau kinases 
More than 20 kinases can phosphorylate tau protein, but it is not clear which 
are responsible for the pathological phosphorylation of tau.  It has been suggested that 
more than one combination of protein kinases is involved in transforming normal tau 
to pathologically hyperphosphorylated tau (63).  The kinases known to phosphorylate 
tau can be classified into three groups:  1) proline-directed protein kinases (PDPK), 
which phosphorylate a serine or threonine followed by a proline residue.  About half 
of the known tau phosphorylation sites are proline-directed sites.  Mitogen activated 
protein kinase (MAPK), cyclin-dependent kinase (cdk1 and 5) and stress activated 
kinases (SAPKs) belong to this group.  Glycogen synthase kinase 3 (GSK3) is 
included in this group as well, although it can also phosphorylate tau at some of the 
serine or threonine residues not followed by a proline residue by recognizing a 
specific Ser-X-X-X-pSer or Ser-X-X-X-D/E motif (68).  2) Non-proline-directed 
protein kinases, which do not require the presence of a proline residue following Ser 
or Thr.  Tau-tubulin kinase (TTK) 1 and 2, microtubule-affinity regulating kinase 
(MARK), cyclic-AMP-dependent kinase (PKA), protein kinase B (PKB/AKT), 
protein kinase C and Ca2+/calmodulin-dependent protein kinase II (CaMPK II) (57, 
69).  MARK is the kinase that phosphorylates tau in the MT-binding repeats, such as 
Ser262, and reduced tau-MT binding by about 10-fold.  3) Tyrosine protein kinases 
such as Src kinase (70).   
 
1.4.5 Tau phosphatases 
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Under physiological conditions, the phosphorylation of tau is maintained 
through the balance between kinases and phosphatases.  Ser/Thr phosphatase protein 
1, 2A, 2B, 2C and 5 (PP1, PP2A, PP2B, PP2C and PP5) are the protein phosphatases 
that are responsible for the dephosphorylation of tau (71).  In vitro reactions have 
shown that these protein phosphatases can de-phosphorylate tau at different sites (57, 
69).   Among these phosphatases, PP2A is the most important one for tau de-
phosphorylation.  PP2A accounts for over 70% of tau phosphatase activity in brain 
(71).  PP2A can counterbalance tau phosphorylation not only by directly 
dephosphorylating tau but also indirectly by reducing tau phosphorylation by 
inhibiting the activity of kinases, such as PKA, CaMPK II and MAP kinase (53). 
 
1.5 Current research on tau aggregation and phosphorylation 
1.5.1 In vitro tau aggregation 
Tau filaments, with similar structure, morphology and immunoacitivity as AD 
tau filaments were formed in vitro (67).  The results of in vitro tau aggregation studies 
suggest that the structural elements of tau contribute differently to its aggregation.  
The results also explain how tau phosphorylation and FTDP-17 mutations change its 
self-aggregation.   
The microtubule binding repeat region is the core part of paired helical 
filaments (reviewed in (72)).  This region alone is sufficient to aggregate into PHFs, 
with two hexapeptide motifs at the beginning of R2 and R3 being the most important 
part in promoting PHF formation by inducing β-structure (reviewed in (73)).  Two 
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FTDP-17 mutants, P301L and DelK280 in the microtubule binding repeats can 
enhance the rate of aggregation by increasing the tendency for forming β-structure in 
this region (reviewed in (74)).  The proline rich region in the N-terminal part of the 
microtubule binding repeats has been shown to inhibit tau aggregation (reviewed in 
(53)). The electronic repulsion between the positively charged amino acids in this 
region inhibits the stacking of β-structure and the presence of proline residues bends 
the protein and masks the microtubule binding repeats (reviewed in (53)).  This 
inhibition can be neutralized by phosphorylation in this region (see below).  The 
extreme N-terminus of tau facilitates the aggregation of tau.  The formation of an 
Alz50 conformation through the binding of the extreme N-terminus and the 
microtubule binding repeats region is an important early step in tau aggregation and 
NFT formation (reviewed in (66)).  The cleavage of the extreme N-terminus will 
abolish the formation of the Alz50 conformation and disrupt PHF formation in vitro 
(75).  The C-terminal region of tau has the opposite effect on tau aggregation.  Tau 
lacking its C-terminal tail has an increased rate of polymerization and more filaments 
were observed compared with full length tau (76).  Tau has been suggested to adopt a 
hairpin structure with C-terminal tails covering the microtubule binding repeats and 
therefore inhibiting the interactions between microtubule binding repeats (reviewed in 
(74)).  This inhibitory effect can be removed by phosphorylation (see above).   
Due to the inhibitory effects of these structural elements on tau aggregation, 
tau does not aggregate spontaneously under physiological pH, temperature, ionic 
strength and concentration in vitro (reviewed in (77)).  Polyanionic compounds such 
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as heparin (78), polyglutamate (79), RNA (80) and fatty acids (81) need to be present 
to induce tau aggregation.  The aggregation process is a typical nucleation-elongation 
process (reviewed in (77)).  The presence of these molecules could overcome the 
energy barriers for aggregation and therefore facilitate tau aggregation.  In vitro tau 
aggregation may involve the formation of a stabilized assembly competent 
conformation, the formation of oligomers and the formation of filaments (reviewed in 
(77, 82)).  The assembly of cysteine-dependent dimers in oxidative conditions has 
been suggested to increase the rate of aggregation, although the dimerization is not 
required for tau aggregation (83, 84).  In addition, the cysteine-independent dimers 
also contribute to tau filament formation (85).  However, because the normal 
physiological condition is reducing, dimer formation may only have subtle 
contributions to tau aggregation. 
 
1.5.2 tau phosphorylation 
Because of the observation that hyperphosphorylated tau is the major 
component of the PHFs and SFs in AD, much effort has been focused on determining 
how phosphorylation changes tau normal function and causes neuronal loss and 
dementia.  Although no clear answer for this question is currently known, progress 
has been achieved in this field by using in vitro models or more physiologically 
relevant animal models.  
 
1.5.2.1 In vitro studies 
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1.5.2.1.1 The studies on tau phosphorylation by pseudophosphorylation tau mutants 
Pseudophosphorylation has been used in other systems to mimic the changes 
induced by phosphorylation (86, 87).  Due to the complexity of tau phosphorylation 
sites, the diversity of tau phosphorylation sites and the highly dynamic turnover of 
phosphorylation in vivo, it is virtually impossible to control the phosphorylation on a 
specific residue or a combination of specific residues by kinase(s).  Therefore, 
phosphorylation is mimicked by replacing serine or threonine residues with 
negatively charged glutamic acid or aspartic acid (76, 88-91).  This replacement 
imitates the changes induced by phosphorylation in the aspects of conformational 
change, microtubule binding and antibody reactivity (88, 92).  Using tau aggregation 
assays, there are some conflicts between the results from different reports.  The 
conflicts between each report may due to the different methods used for assaying the 
amount of polymerization (Thioflavine S fluorescence vs. laser light scattering vs. 
transmission electron microscopy) and/or different reaction conditions, such as 
protein concentration and/or inducer concentration.  The results obtained from the 
studies on pseudophosphorylation are listed in Table 1.1.  In addition to the changes 
on conformation, tau self-aggregation, MT binding and stimulation of MT assembly, 
pseudophosphorylated tau was also shown to have lower binding affinity for PP2A 
and neural membrane cortex, and have increased phosphorylation at other sites (90, 
91, 93).  At the same time, cells expressing pseudophosphorylated tau were also 
found to have increased caspase 3 activity, increased cytotoxicity and increased 
apoptosis with or without detectable tau aggregates (94-96).  These results also 
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suggest that the toxicity of phosphorylated tau might not depend on the formation of 
tau aggregates.   
Considering the difference between heterogeneous phosphorylation by kinases 
and homogeneous pseudophosphorylation, pseudophosphorylation can not 
completely mimic the phosphorylation changes.  However, it is still an invaluable tool 
to answer the questions of phosphorylation at specific sites in tau functions. 
 
1.5.2.1.2 The studies on kinases and phosphatases 
1.5.2.1.2.1 Glycogen synthase kinase - 3β (GSK-3β) 
GSK-3β is a constitutively active kinase involved in many of the 
physiological processes from glycogen metabolism to gene transcription (97).  It is a 
proline directed protein kinase (68).  It has been shown to play roles in both familial 
and sporadic forms of AD (97).  GSK-3β is highly expressed in neuronal cell bodies 
and their processes, and also co-localizes with NFTs in AD brain (97).  In addition, 
the expression level of GSK-3β is significantly increased in AD brain compared with 
control brains (98).  After examining the sites on tau that are phosphorylated by GSK-
3β, at least 23 sites (T69, T175, T181, S184, S198, S199, S202, S210, T212, S214, 
T217, T231, S235, S237, S258, S262, S289, S356, S396, S400 and S413) are 
phosphorylated by GSK-3β and most of the sites overlap with those found in PHF tau 
(99).  This evidence makes GSK-3β a leading candidate for inducing the progression 
of AD.  The in vitro studies on GSK-3β and its inhibitor lithium further support this 
hypothesis.  Our in vitro study with GSK-3β phosphorylated tau showed that GSK-3β  
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175(96) n/d ▼ n/d ▲ 
199(100) n/d n/d n/d ▲ 
202(101) ■ ▼ n/d ■ 
205(101) ■ ▼ n/d ■ 
212(100) n/d n/d n/d ▲ 
214(100) n/d n/d n/d ▲ 
217(92, 102) n/d n/d ▼ ▼(92)/■(102) 
231(100) n/d n/d n/d ■ 
235(100) n/d n/d n/d ▼ 
262(100, 102) n/d n/d n/d ■ 
327(88) ▼ ■ ■ n/d 
396(92) n/d n/d n/d ■ 
409(100) n/d n/d n/d ■ 
422(92, 100, 102) n/d n/d ■ ▲(92)/■(100, 
102) 
111/153(92, 102) n/d n/d ▼ ▼(92)/■(102) 
202/205(101) ■ ▼ n/d ■ 
212/214(100, 103) ■ n/d n/d ▲ 
231/235(92, 93, 100) n/d ▼ ■(92)/▼ (93)  ▲(100)/■(102) 
156/327(88) ▼ ■ ▼ n/d 
262/356(92) n/d n/d ▼ ■ 
396/404(76, 93, 100, 103) ▼ ■ ▼ ▲ 
403/404(92, 102) n/d n/d ■ ■ 
175/176/181(92) n/d n/d ▼ ▼ 
199/202/205(100) n/d n/d n/d ▲ 
396/403/404(102) n/d n/d n/d ▲ 
400/403/404(92) n/d n/d ▼ ■ 
409/412/413(92) n/d n/d ■ ▼ 
208/210/212/214(92) n/d n/d ▼ ▼ 
231/235/393/404(93) ▼ ▼ ▼ ■ 
396/400/403/409(92) n/d n/d ■ ■ 
195/198/199/202/205(92) n/d  n/d ▼ ▼ 
208/210/212/214/217(92) n/d n/d ▼ ■ 
198/199/202/231/235(91) ▼ n/d ▼ ▼ 
396/404/409/413/422(91, 94) ▼ n/d ■ ■ 
199/202/205/212/214/396/404(103) ▼ n/d ■ ▲ 
198/199/202/231/235/396/404/409/413/
422(89-91, 94) 
▼ ▼ ▼ ▼ 
 ■: no significant change was observed; 
▼: significantly decreased; In the column on conformational change, ▼ represents decreased 
electrophoresis mobility/ opened conformation (103). 
▲: significantly increased. 
 n/d: not determined 
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can induce an SDS-resistant conformational change similar to PHF tau.  GSK-3β 
phosphorylation is sufficient to promote the formation of tangle-like aggregates from 
arachidonic acid (ARA) induced tau filaments or concurrently with tau fibrillation 
(104, 105) .  GSK-3β phosphorylation also decreases the microtubule binding ability 
of tau, the ability of tau to promote MT assembly and  to stabilize MT (106), and 
therefore changes the cellular microtubule organization and axon dynamics (53, 107).  
These changes in tau function can be reduced by lithium which inhibits GSK-3β 
activity.  By introducing lithium to the cultured human NT2N neurons to reduce the 
phosphorylation of tau, tau had an enhanced binding to MT and increased ability to 
promote MT assembly (108).  
 
1.5.2.1.2.2 Cyclin-dependent kinase (cdk5) 
Cdk5, a proline-directed protein kinase, is a member of the cyclin-dependent 
kinase family (109).  Unlike other cyclin-dependent kinases, cdk5 is not directly 
involved in cell cycle control.  Cdk5 is present in post-mitotic neurons, concentrated 
in axons and is essential for embryonic development (110, 111).  Cdk5 activity 
requires the presence of its activator (p39 or p35) or their proteolytic products (p35 or 
p25) which are exclusively present in post-mitotic neurons (112).  Like GSK-3β, 
cdk5 and its activator have been found in brain and to be physical interacting with 
MT (113).   Cdk5 can phosphorylate tau at sites that are phosphorylated in AD (S113, 
S184, S198, S208, S214, T231, S235, S396, and S404).  Cdk5 phosphorylated tau 
shows a band shift on SDS-PAGE similar to PHF tau (113-115).  Deregulation of 
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cdk5 has been found in human neurodegeneration, with an increased expression level 
of cdk5 and p25 in neurons bearing early stage NFTs (109, 116).  The 
phosphorylation of tau with cdk5 can also promote the subsequent phosphorylation 
by GSK-3β (117).   The combination of cdk5 and GSK-3β can convert normal tau to 
PHF tau and can restore the ability of self-aggregation and microtubule inhibitory 
activities (63).  These features make cdk5 another attractive candidate responsible for 
disease related abnormal hyperphosphorylation.  An in vitro phosphorylation study of 
cdk5 on tau showed that phosphorylation severely inhibited the ability of tau to 
promote microtubule assembly.  Phosphorylated tau was released from MT and 
resulted in the depolymerization of tubulin (49).  In primary cultured neurons, 
constitutive activation and mislocalization of cdk5 induced by the presence of p25 
resulted in the hyperphosphorylation of tau and these changes were sufficient to 
disrupt the cytoskeleton, disrupt neuron morphologies and promote the apoptosis of 
primary neurons (118, 119).  
 
1.5.2.1.2.3 Ser/Thr phosphatase protein 2A (PP2A) 
PP2A accounts for over 70% of tau phosphatase activity (71, 120).  It is a 
multimeric enzyme with three subunits: a scaffolding A-subunit, a large regulatory B-
subunit and a catalytic subunit C (121).    Site-specific de-phosphorylation of tau by 
PP2A in vitro has been observed at S46, T188, S199, S202, T205, T212, S214, T217, 
T231, S256, S262, S396, T403, S404 and S422 (63).  PP2A was found to localize on 
MT and bind directly to tau (122, 123).  PP2A is thought to be related to AD because 
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its expression level and activity are decreased in AD brain (124, 125).  And the down-
regulated PP2A is selectively found in the neurons with pre-tangles and tangles (126, 
127).  In addition to the overall mRNA level, mRNAs of catalytic and regulatory 
subunits are also selectively decreased in these neurons (128).  The activity of PP2A 
is negatively correlated to the increase of tau phosphorylation at most of the AD sites 
(71, 129). 
In vitro studies showed PP2A can de-phosphorylate PHF tau or pre-
phosphorylated recombinant tau.  The de-phosphorylation of tau by PP2A removes 
most of the phosphates from tau and restores its biological characteristics, such as 
SDS-resistant conformational change, MT binding activity and promoting MT 
assembly.  At the same time the de-phosphorylated PHF tau loses its ability to 
aggregate into PHFs and NFTs (62, 120, 130).  PP2A inhibitors such as okadaic acid, 
I1PP2A and I2PP2A can increase the abnormal hyperphosphorylation of tau in 
cultured cells or in rat brain slices.  Tau in rat brain slices treated with the PP2A 
inhibitor, okadaic acid, had pathological changes that resembled the pathologies of 
AD.  These changes included an increased AD-like hyperphosphorylation, decreased 
MT binding and MT assembly,  and the accumulation of tau in tangle-prone neurons 
(131).  Further examination of kinase activities showed the increase in tau 
phosphorylation was not only through the direct down-regulation of de-
phosphorylation but indirectly through the regulation of the activity of GSK-3, cdk5 
and other kinases (132-135).  I1PP2A and I2PP2A are endogenous PP2A inhibitors.  
Their expression levels in AD are also changed together with the level of PP2A (136).  
 31
The increased level of I1PP2A and I2PP2A can further decrease the PP2A activity 
and this idea was confirmed in cultured cells (137).  PC12 cells doubly transfected 
with tau ht40 and I1PP2A/I2PP2A had increased tau phosphorylation and impaired 
MT networks.  Increased cell death was also observed in this model (138, 139). 
 
1.5.2.2 In vivo animal models 
In vivo animal models were used to study the link between tau and neuron 
pathology.  The results from these studies shed light on the understanding of toxic 
species in AD and tauopathies. 
 
1.5.2.2.1 Transgenic C. elegans models 
C. elegans is a short-lived, small animal with a central nervous system and a 
brain.  Current results from C. elegans expressing human tau partially resembled the 
situation in human neurodegeneration (140-142).  Therefore, C. elegans can be used 
as a simplified animal model to study tauopathies.   In the C. elegans models 
expressing wild type (1N4R, 0N4R or 0N3R) and FTDP-17 mutant (P301L, V337M 
and R406W) tau, hyperphosphorylated tau, impaired neuronal function and abnormal 
neuron morphology were observed (140-142).  The mutant tau had more severe 
phenotypes compared with wild type tau.  Tau was phosphorylated at many of the 
sites found in AD tau, such as S199, S202, T231, S396 and S404.  The SDS-resistant 
conformational change was also observed in these phosphorylated tau (140).  In the 
0N3R or 0N4R tau expressing C. elegans, no neuronal degeneration happened (141).  
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However, in the 1N4R tau expression worms, loss of axons and neurons, and 
structural damage to axonal tracks were observed (142).  A decreased life span was 
also associated with these changes.  Insoluble PHF-like tau accumulations were found 
in these models but after the appearance of abnormal behavior (142).  This 
observation suggested that aggregation may not be required for tau-induced neuronal 
dysfunction and soluble hyperphosphorylated tau may be the neurotoxic species.  The 
effect of phosphorylation on tau function was also tested in C. elegans model with co-
expression of GSK-3/cdk5 and tau (141).  More severe phenotypes were observed 
compared with C. elegans expressing wild type tau alone.  The C. elegans expressing 
a pseudohyperphosphorylated form of tau showed similar changes as the double 
transgenic (Tg) worms (140).   
 
1.5.2.2.2 Transgenic Drosophila models 
Human genes and Drosophila genes have high similarities.  At least 50% of 
Drosophila genes have a human homologs and more than 70% of human disease 
genes, including MAPT (human tau gene), have Drosophila homologs (143, 144).  
This makes Drosophila a good model to study human disease.  Some fundamental 
characteristics of tauopathies were recapitulated in Drosophila expressing a human 
tau gene, including abnormal tau phosphorylation and adult onset, progressive 
neurodegeneration (144, 145).  In Drosophila models expressing wild type or mutant 
(R406W, V337M) human tau, neurodegeneration was observed.  Both wild type and 
mutant tau in these models showed an AD-like abnormal hyperphosphorylation and 
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conformational change with tau concentrating abnormally in the areas of 
neurodegeneration.  These transgenic fruit flies also had a shorter life span compared 
to non-transgenic controls.  All these changes were greater in Drosophila expressing 
mutant tau than those expressing wild type tau (146).  However, neurofibrillary 
tangles were not found in this model, not even in the degenerative neuronal cells.  A 
similar result was reported by another group (147).  In this model, the observed 
neurodegeneration was dissociated from the presence of NFTs.  However, when 
human tau was co-expressed with GSK-3 Drosophila homolog, Shaggy, they 
observed a severe neurodegeneration induced by tau and a NFT-like pathology 
composed of hyperphosphorylated tau was observed (147).   
In two other Drosophila models with motor neuron dysfunction, no neuronal 
death was observed.  The malfunction in motor neurons was associated with disrupted 
axonal transportation, such as: loss of axons, abnormal axon bundling and axonal 
swelling (148, 149).  These pathological changes were phosphorylation dependent 
and were enhanced by co-expression of GSK-3β (149).  The results from these 
Drosophila models suggested that the early modifications of tau, such as 
phosphorylation and conformational changes may be the toxic substrates of 
tauopathies and NFT formation may not be necessary for neurodegeneration.   
Drosophila models were also used to study tau phosphorylation and screen for 
kinases and phosphatases involved in neurodegeneration.  From the result of the 
Drosophila expressing a pseudophosphorylated form of tau, phosphorylation was 
found to directly precede apoptosis and none of the fourteen sites they checked (T111, 
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T153, S175, T181, S199, S202, T205, T212, T217, T231, S235, S396, S404 and 
S422) played a dominant role in controlling tau toxicity(150, 151).  From the results 
of a genetic modifier screen and other biochemical approaches, PAR-1 kinase (the 
Drosophila homolog of MARK kinase), GSK-3, cdk5/p35, PKA, JNK(c-Jun NH2-
terminal kinase) and PP2A were thought to be important for neurodegeneration, as 
have been reported for the in vitro studies (152-154). 
 
1.5.2.2.3 Transgenic mouse models 
Transgenic (Tg) mouse models have been used to model the human 
neurodegenerative diseases and have successfully recapitulated the pathological 
changes in human tauopathies.  However, since mouse brain has its own endogenous 
tau and conserved phosphorylation sites are the same as those in AD tau, many 
aspects need to be taken into consideration when interpreting these tau-expressing 
mouse models.  In mouse brain, only 4R isoforms are expressed and the results from 
some of the Tg mouse models suggest that the presence of endogenous tau may affect 
expression or splicing of the exogenous tau, thereby affecting the phenotype and 
pathology of exogenous human tau (155, 156).  However, mice with endogenous tau 
deleted by knock-out seem to be normal immunohistologically and functionally, and 
showed no changes in axonal elongation (157).  This may due to the presence of other 
microtubule binding proteins, such as MAP1 and MAP2.  Secondly, the promoters 
used in different Tg mouse models will change the location and level of tau 
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expression, which has been proven to be extremely relevant to the pathologies 
observed.   
The first Tg mouse model was generated in 1995 by Gotz J with his 
colleagues.  The longest human wild type tau (2N4R) was expressed in Tg mouse 
brain under the control of human Thy-1 promoter (158).  A relatively low level of tau 
was expressed in nerve cell bodies, axons and dendrites (158).   The antibody studies 
showed exogenous human tau was phosphorylated at many AD-related sites.  
However, NFTs did not form in this model (158).  After this, other Tg mouse models 
were generated expressing different wild type tau isoforms and with different 
promoters.  With two exceptions, most of these wild type human tau expression mice  
failed to produce NFTs (156, 159).    Different types of neurodysfunctions to different 
levels were observed in these mouse models.  The pathologies included but were not 
limited to:  axonal degeneration in brain and spinal cord associated with progressive 
nerve cell dysfunction, amyotrophy and motor deficits, tau mislocated in 
somatodendrites, astrocytic expression of tau, AD-like tau hyperphosphorylation, 
abnormal conformational change and ubiquitination (160-162).  The presence of 
abnormal neuronal function without formation of NFTs in the CNS of mice 
expressing human tau suggested NFT might not be necessary for neuron malfunction.   
In a Tg mouse model expressing human 0N3R tau under the control of mouse 
prion promoter (MoPrP), NFT pathologies occurred for the first time (159).  Tau 
expression was observed in CNS and the insoluble, hyperphosphorylated tau 
coalesced in intraneuronal inclusions in cortical and brainstem neurons in an age-
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dependent manner (159).  NFT-like inclusions were observed in the hippocampus of 
the aged mice at around 18 to 20 months (163).  Axon degeneration, diminished 
axonal transport and motor weakness associated with the age-dependent CNS 
pathologies were also observed in this model (159).  This model was the first Tg 
mouse model recapitulating key features of tauopathies. 
Instead of expressing only one of the tau isoforms, Tg mice expressing all six 
tau isoforms were generated on the background of endogenous mouse tau or the 
murine tau-null background (155, 156).  With the presence of endogenous murine tau, 
although axonal swelling correlatting with a hind-limb abnormality were observed, no 
NFTs formed in mouse brain.  Human tau expressed in mouse brain was 
hyperphosphorylated and in an abnormal conformation, but neuromorphology was 
essentially normal (155).  However, all six human isoforms expressing on the murine 
tau-null background induced an age-related neuropathology with the presence of 
PHFs in the cell bodies and dendrites of neurons.  Tau in mice brain was 
hyperphosphorylated at AD-relevant sites and had an AD-like conformational change 
(156).  The comparison between these two models suggested the endogenous 3R 
murine tau may have an inhibitory effect on the neuropathologies induced by the 
presence of exogenous human tau. 
Because most of the Tg mouse models expressing wild type tau failed to 
recapitulate the human tauopathies, Tg mouse models expressing FTDP-17 mutants 
in wt tau background were generated.  FTDP-17 mutants resulted in an early-onset of 
neurodegeneration and had an increased tendency to be phosphorylated and aggregate 
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in vitro, and NFT formation was achieved in most of these Tg mouse models.  
P301L/S were the two FTDP-17 mutants used most frequently, at least seven Tg 
mouse lines expressing these two mutants have been generated. 
The first Tg mouse model of human P301L used 0N4R human tau isoform 
under the control of MoPrP (164, 165).  The mice had a shortened life span with NFT 
formation and neuronal loss.  An age- and gene-dose-dependent motor and behavioral 
deficit was associated with the formation  of NFT and Pick body like neuronal lesions 
in brain (164, 165).  Pre-tangle tau filaments were also found in the cortex, 
hippocampus and basal ganglia.  Tau in filaments and NFTs was 
hyperphosphorylated and had an AD-like conformational change (164, 165).  Axonal 
degeneration, neurogenic atrophy and gliosis were also observed in the areas 
associated with NFTs and tau filaments (164, 165).  A tetracycline-regulated 0N4R 
P301L human tau-expressing Tg mouse model, controlled under CaMK-II promoter, 
was generated by SantaCruz and his colleagues (166-168).  In this model, continued 
expression of human P301L resulted in an age-dependent development of dementia.  
In the young Tg mice, motor defects were observed.  Tau in this stage was 
hyperphosphorylated and had a conformational change.  As the mice aged, NFTs 
were observed in the neocortex and hippocampus (166-168).  The accumulation of 
sarkosyl-insoluble tau was observed and the transmission electron microscopy (TEM) 
examination of this insoluble tau showed it was in the form of SFs.  In later stages, 
forebrain atrophy and up to 80% neuronal loss in the hippocampus were associated 
with cognitive impairments.  These neurodegenerative phenotypes were recovered 
 38
and further neuronal loss was stopped by suppressing of the expression of human 
P301L tau, although NFTs continued to accumulate.  The dissociation of 
neurofibrillary pathology with NFTs in this model again suggested NFTs were not 
sufficient to cause cognitive decline or neuronal death, at least in this model.  The Tg 
mouse models expressing the P301L/S mutant on other human tau isoforms (2N4R 
and 1N4R) under the control of other promoters (mThy-1.2, MoPrP and murine thyl 
promoter) also formed NFTs and different types of neurofibrillary pathologies (169-
175).  The mislocated, hyperphosphorylated tau formed SFs and twisted ribbons, 
which further clustered into NFTs.  Some of the mouse endogenous tau also co-
aggregated with exogenous human tau.  Astrocytosis and neuronal apoptosis, neuron 
loss, synapse loss and impaired synaptic function, neuron atrophy, motor malfunction 
and reduced life span were observed in these Tg mouse models.  In some cases, 
microglial activation and neuroinflammation associated with these changes (169, 172).  
Other FTDP-17 mutants such as V337M, R406W and DelK280 tau were also 
used in Tg mouse models.  Most of the phenotypes were similar as those observed in 
P301L/S tau Tg mice (176-180).  In the Tg mouse model generated by Mocanu et al., 
instead of using full length tau, the MT binding repeat domain of human tau with 
DelK280 mutation was used.  The MT-binding repeat region has been shown to have 
a higher tendency to self-aggregate in vitro and cultured cells (181). Abnormal tau 
aggregation and NFT formation associated with missorting of tau in the 
somatodendritic compartment, astrogliosis, loss of synapses and neurons were 
observed in this model. 
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In addition, human tau with more than one site of mutation was expressed in 
some of the Tg mouse models (182-184).  Most of the neurofibrillary phenotypes 
were similar as these in the Tg mice expressing human tau with a single mutation.  In 
the Tg mouse model with double mutant tau (G272V/P301S), no motor dysfunction 
appeared (182).  This made it possible to study the Tg mice with behavioral 
experiments and the Tg mice in the late stages of tau pathology.   NFT-like inclusions, 
ghost tangles, PHF-like filaments and mild astrogliosis were observed in this Tg 
mouse model.  Other pathologies associated with tauopathies such as impaired 
behavioral characteristics, increased anxiety, delayed learning and reduced spatial 
memory were observed in this model with no change in motor activity.   
Glial pathologies occur in some of the tauopathies, such as FTDP-17, PSP and 
CBD.  Some Tg mice expressing wild type or mutant tau recapitulated the glial side 
of the tauopathies (185-188).  Phosphorylated fibrillary tau was found in astrocytes 
and oligodendrocytes associated with degeneration of these cells.  The ultrastructure 
of the tau filaments found in glials was similar to those found in neurons and these tau 
filaments were ubiquitin positive (185-188).   
Aβ deposition is another diagnostic characteristic of AD.  To study the link 
between Aβ and tau aggregation, double or triple Tg mouse models were generated 
by crossing the Tg mice.  Some conflicting results were shown in these studies.  In 
some studies, Aβ was not  necessarily associated with NFT pathologies (189).  
However, in other studies, Aβ was shown to influence NFT formation, even by 
injecting Aβ oligomers into brains of human tau expressing mice (184, 190-193).   
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CHAPTER 2 RATIONALE AND AIMS 
The microtubule associate protein tau loses its normal function and aggregates 
into insoluble filaments (PHFs and SFs) in Alzheimer’s disease (1.2.1).  These 
insoluble filaments can further aggregate into intracellular neurofibrillary tangles 
(NFTs) and the number of NFTs is closely related to the severity of dementia (1.2.1).  
NFTs are also found in some other neurodegenerative diseases such as progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick’s disease (PiD) and 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) 
(1.2.2, 1.3).  A distinct feature of tau isolated from NFTs is abnormal 
hyperphosphorylation (1.3.2).  The abnormal hyperphosphorylation of tau is thought 
to be a key event in the progression of AD and tauopathies (1.5.2).  
Hyperphosphorylated tau has a reduced MT binding affinity and a reduced ability to 
promote MT assembly (1.5.3).  In addition, hyperphosphorylated tau is prone to self-
aggregate (1.5.3).   
To date, about 45 sites have been identified to be phosphorylated in PHF tau 
(1.3.2).  However, it is not clear which kinase(s) is responsible for the 
hyperphosphorylation of tau.  At least 20 kinases can phosphorylate tau and most 
likely there are more than one combinations of kinases that might be involved in this 
process (1.5.4).  Among these kinases, glycogen synthase kinase - 3β (GSK-3β) is an 
attractive candidate (1.6.1.2).  According to our previous observation, GSK-3β can 
phosphorylate monomeric or polymerized tau at eleven or five sites respectively (104, 
105).  Phosphorylation at these sites did not change the amount of tau polymerization 
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induced with arachidonic acid (ARA), but was sufficient to cause tau filaments to 
coalesce into tangle-like aggregates similar to those isolated from AD brain. 
The general aim of this study is to understand the effect of 
pseudohyperphosphorylation at GSK-3β sites on tau function.   Our previous studies 
showed the pseudophosphorylation at S202 and T205, which are GSK-3β 
phosphorylation sites, resulted in only subtle effects on tau function (101).  However, 
it is not clear whether the pseudohyperphosphorylation at multiple GSK-3β 
phosphorylation sites will induce a greater change.  We hypothesize that the 
pseudohyperphosphorylation at multiple sites will change tau function more 
significanlty than pseudophosphorylation at single or double sites.  To test this 
hypothesis, we generated variants with six (6-Phos) or seven (7-Phos) 
pseudophosphorylation changes.  These sites are S199, S202, T205, T231, S235, 
S396 and S404.  Five of these seven sites (S199, T205, T231, S396 and S404) are the 
five sites identified to be phosphorylated by GSK-3β when polymerized tau was used 
as the substrate.  S202 was added to the core five sites since the antibody AT8 
recognizes phosphorylation at both S199 and S202 (43).  For similar reasons, S235, 
which is recognized by antibody TG-3 together with T231, was added to 6-Phos to 
generate 7-Phos (13).  Single, double and triple pseudophosphorylation mutants were 
generated and used to test the possibility that fewer sites could have similar effects on 
tau function as the pseudohyperphosphorylated tau.  The pseudophosphorylation 
mutants at other sites (T212, S208 and S210) were included in the study as well.   
T212E was included because it was shown in another study to significantly increase 
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the amount of ARA-induced tau polymerization (1.5.1.1).  S208 and S210 are the 
sites phosphorylated by a non-proline directed protein kinase, tau-tubulin kinase 
(TTK).  These two sites locate in the same region as GSK-3β phosphorylation sites 
and are also found to be phosphorylated in AD.   
These pseudophosphorylation variants were assayed for changes on 
electrophoretic mobility, microtubule binding and ARA-induced polymerization.  The 
results from this study showed that pseudohyperphosphorylation can decrease the 
binding affinity of tau to MT and reduce ARA-initiated rates of nucleation and 
polymerization.  The combination of these changes could explain the increased 
cytotoxicity of hyperphosphorylated tau.  The observation of tangle like tau 
aggregates in our study also explains the potential beneficial role of tau 
polymerization and NFT formation. 
In vitro ARA-induced tau polymerization has previously been shown to 
depend both on tau concentration and the inducer concentration (1.5.1).  The biphasic 
dependence is also observed in all of our pseudophosphorylation mutants.  However, 
the mechanism of ARA-induced tau polymerization is not understood.  In the 
appendix, the mechanism of ARA-induced tau polymerization is studied.  The results 
suggest that ARA can induce tau polymerization both as large micelles and as 
monomers (or small micelles).  The morphology of ARA-induced filaments is 
affected by the molecular nature of ARA.  I also found that the amount and 
morphology of tau filaments were affected by surface area : volume ratio of the 
reaction. 
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CHAPTER 3 MATERALS AND METHODS 
3.1 Tau protein purification 
3.1.1 Generation of  mutant tau constructs  
As mentioned above, 9 sites (S199, S202, T205, S208, S210, T212, T231 and 
S235) were chosen to generate the pseudophosphorylation mutants.  Fifteen mutants 
from the combination of these 9 sites were generated by replacing serine/threonine 
with glutamic acid/aspartic acid on the longest isoform of human tau (ht40, 441 
amino acids).  QuikChange Site-Directed Mutagenesis Kit from Stratagene (La Jolla, 
CA) was used to generate these site-directed mutants.  The single mutants were 
constructed first and confirmed by sequence analysis.  The primers used for site-
directed mutagenesis were: 
S199E:  5’-GCA GCG GCT ACA GCG AGC CCG GCT CCC CAG G-3’ and  
              5’-CCT GGG GAG CCG GGC TCG CTG TAG CCG CTG C-3’               
S202E: 5’-CAG CAG CCC CGG CGA ACC AGG CAC TCC CG-3’ and 
             5’-CGG GAG TGC CTG GTT CGC CGG GGC TGC TG-3’ 
T205E: 5’-CCG GCT CCC CAG GCG AAC CCG GCA GCC GCT C-3’ and  
             5’-GAG CGG CTG CCG GGT TCG CCT GGG GAG CCG G-3’ 
S208D: 5’-GGC ACT CCC GGC GAC CGC TCC CGC AC-3’ and 
             5’-GTG CGG GAG CGG TCG CCG GGA GTG CC-3’              
S210D: 5’-CCC GGC AGC CGC GAC CGC ACC CCG TC-3’ and 
             5’-GAC GGG GTG CGG TCG CGG CTG CCG GG-3’ 
T212E: 5’-GCA GCC GCT CCC GCG AGC CGT CCC TTC CAA C-3’ and 
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             5’-GTT GGA AGG GAC GGC TCG CGG GAG CGG CTG C-3’ 
T231E: 5’-TGG CAG TGG TCC GTG AGC CAC CCA AGT CGC CG-3’ and 
             5’-CGG CGA CTT GGG TGG CTC ACG GAC CAC TGC CA-3’ 
S235D: 5’-CCG TAC TCC ACC CAA GGA TCC GTC TTC CGC CAA GAG-3’ 
and       5’-CTC TTG GCG GAA GAC GGA TCC TTG GGT GGA GTA CGG-3’ 
The double mutants were generated on the background of single mutants and 
the triple mutant on the background of the double mutant.  For the 6-Phos mutant, 
site-directed S to E substitution at site 199/202/205 was introduced to the 
S396/S404E parent clone generating a 5-Phos clone, followed by the T to E 
substitution at site 231 on the 5 -Phos background.    For the 7-Phos mutant, the S to 
E substitution at site 235 was introduced to the 6-Phos parent clone.  All these 
mutants were confirmed by sequence analysis.  The constructs for S202E, T205E, 
S202/T205E were made by Dr. Carolyn Rankin and the constructs for 5-Phos, 6-Phos 
and 7-Phos were made by Min He.  The constructs for S396/404E and P301L were 
the generous gifts from Dr. Lester I. Binder.  The constructs for the 
pseudophosphorylation mutants were transformed into BL21 (DE3) Competent Cells 
(Sigma, St. Louis, MO)  and stored at -80ºC (101).   
 
3.1.2 Purification of tau variants  
BL21 (DE3) competent cells containing wild type or mutant tau cDNA-
plasmid were grown in 60 ml Luria Broth (LB) overnight at 26 ºC until OD600 was 
close to 0.5 and then used to seed three flasks containing 1.8 liter LB which were 
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incubated at 37 ºC.  IPTG was added to the culture to induce the expression of tau 
protein for an additional 2 hours when OD600 reached 0.7 - 0.8.  Cells were harvested 
by centrifugation and resuspended in 25 ml ice cold 1x lysis buffer (500mM NaCl, 
10mM Tris Base pH 8, and 5mM imidazole).  Cells were lysed by passing through a 
French Press cell disrupter (Thermo Electron Corporation, Waltham, MA).  Tau 
protein was purified using Nickel affinity column chromatography followed by gel 
filtration through a Superdex 200 column using ACTA fast protein liquid 
chromatography (FPLC) (Amersham Biosciences, Piscataway, NJ).  The purity of the 
protein was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.  
Protein concentration was determined by commercial BCA assay (Pierce Chemical, 
Rockford, IL) using bovine serum albumin (Pierce Chemical, Rockford, IL) as a 
standard (101).  
 
3.2 SDS – PAGE and SDS – PAGE with urea  
Protein samples (wild type or pseudophosphorylation mutants, 1µg per lane) 
were boiled for 5 min in sample buffer containing 2% SDS and 1% β-mecaptoethanol, 
fractionated on 15% SDS-PAGE and stained with Commassie brilliant blue (91, 101).  
For denaturing SDS-PAGE, protein samples (1µg per lane) were boiled for 5 min in 
sample buffer containing 2% SDS, 1% β-mecaptoethanol and 6 M urea.  Samples 
were fractionated on 15% SDS-PAGE containing 6 M urea and stained with 
Commassie brilliant blue (91, 101).  The molecular weight of each mutant was 
determined from the distance on the gel. 
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3.3 In vitro polymerization reactions 
3.3.1 Standard polymerization reactions 
Two micromolar tau protein (wild type or pseudophosphorylation mutants) 
were incubated in polymerization buffer (10 mM HEPES pH 7.64, 100 mM NaCl, 0.1 
mM EDTA and 5 mM DTT) at room temperature in the presence of 25 - 150 µM 
arachidonic acid (ARA) (in ethanol, final concentration of ethanol was 3.75%) for 16 
– 20 hr (194).   
 
3.3.2 Polymerization of pseudophosphorylation mutant tau combination  
Three hundred and thirty nanomolar of each of the pseudophosphorylation 
mutant tau (S199E, S202/T205E, S208D, T212E, T231E/S235D, and S396/404E) 
were mixed and incubated in polymerization buffer (10 mM HEPES Ph 7.64, 100 
mM NaCl, 0.1 mM EDTA and 5 mM DTT) with 25 or 75 µM ARA (in ethanol, final 
concentration of ethanol was 3.75%), 0.3 mM MgCl2, 0.2 mM ATP and 20 µM 
Thioflavine S at 30 ºC for 20 hr. 
 
3.4 Thioflavine S fluorescence  
Thioflavine S (ThS) was added to tau polymerization reactions after 20 hr 
incubation at a final concentration of 20 µM.  The resulting fluorescence was 
measured in a 96-well plate in a Cary Eclipse fluorescence spectrophotometer (Varian 
Analytical Instruments, Walnut Creek, CA) with excitation and emission wave 
lengths at 440 and 520 nm, respectively (194).   
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3.5 Right angle laser light scattering 
Tau polymerization reactions were transferred into 5 х 5 mm optical glass 
fluorometer cuvettes (Starna Cells, Atascadero, CA) and illuminated with a 5 mW 
solid state laser (λ = 475 nm, B & E Tek, Inc., Newark, DE).  Images were captured 
at a right angle to the incident light using a SONY XC-ST270 digital camera.  
Captured images were imported into Adobe Photoshop 7.0.1 and the intensity of the 
scattered light equaled the value assigned to the histogram of a 15 х 15 pixel box.  
The scattering at zero time point (dark current) was subtracted from all the 
measurements.  All images were captured at an aperture of f5.6 – 8 or f8 and then 
normalized to the intensity corresponding to the exposure at f5.6 – 8 (101).   
 
3.6 Transmission electron microscopy 
3.6.1 Standard polymerization reactions 
Tau polymerization reactions after 20 hr incubation were diluted 10-fold with 
polymerization buffer then fixed with 2% glutaraldehyde (in water) for 5 min.  Ten 
microliters of fixed samples were placed on formvar-carbon coated grids for 1 min, 
washed with water, blotted, washed with 2% uranyl acetate, blotted again, stained 
with 2% uranyl acetate for another minute, and then blotted dry.  Grids were viewed 
with a TECNAI G2 20 electron microscope (FEI Company, Hillsboro, OR) and digital 
images were captured with the Gatan Digital Micrograph imaging system.  The 
pictures were analyzed with Optimas image analysis program for the filament length 
and number of filaments (101). 
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3.6.2 Polymerization of pseudophosphorylation mutant tau combinations  
Tau polymerization reaction after 20 hr incubation were diluted 5-fold with 
polymerization buffer, then applied to the grids for 1 min.  The edge of the grid was 
then touched to filter paper to blot away excess liquid.  One percent uranyl acetate 
was put on grids and stained for one minute then blotted.  Grids were viewed with a 
JEOL 1299 EXII electron microscope and digital images were captured with the 
MegaViewII imaging system (Soft Imaging System, GmbH Münster, Germany) (101).   
 
3.7 Kinetics of polymerization 
The polymerization reaction of wild type and pseudophosphorylation tau 
variants at 2 µM protein concentration induced with 75 µM ARA were set up in the 5 
х 5 mm optical glass fluorometer cuvettes and then monitored by LLS as described 
above at regular intervals for 20 hr.  Images were imported into Adobe Photoshop 7. 
0. 1. The intensity of laser light scattering was measured by the histogram function as 












where y is the intensity of laser light scattering measured at time t; ti is the inflection 
point corresponding to the maximum increasing rate of laser light scattering; a is the 
maximum amount of laser light scattering at equilibrium; and b equals to 1/Kapp.  Kapp 
is proportional to the rate of filament elongation.  The lag time for polymerization is 
equal to the value of ti – b, which was defined as the time when significant amount of 
polymerization appears (100, 195).   
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3.8 In vitro microtubule binding assay 
3.8.1 Preparation of paclitaxel stabilized microtubules 
To prepare paclitaxel stabilized microtubules, 20 µl of 1.5 mg/ml tubulin was 
incubated with 2.5 µl cushion buffer (80 mM PIPES, pH 7.0, 2 mM MgCl2, 0.5 mM 
EGTA in 50% (v/v) glycerol) for 20 min and then diluted into 200 µl general tubulin 
buffer (80 mM PIPES, pH 7.0, 2 mM MgCl2, 0.5 mM EGTA) plus 2µM paclitaxel.  
The concentration of the stable MTs was 1.62 µM tubulin dimers.  The tubulin was 
the generous gift from Dr. Richard H.Himes. 
 
3.8.2 Microtubule binding assay 
The microtubule binding assay was performed in general tubulin buffer (80 
mM PIPES, pH 7.0, 2 mM MgCl2, 0.5 mM EGTA).  Tau protein ranging from 0.125 
µM to 10 µM was mixed with paclitaxel stabilized microtubules (final concentration 
of 1.62 µM tubulin dimer) in a 50 µl reaction.  Samples were incubated at room 
temperature for 30 min, and centrifuged in a Beckman Optima TLX ultracentrifuge at 
100,000 х g for 5 min.  The microtubule and tau bound to the microtubules were 
sedimented during centrifugation.  The pellets were resuspended with 1x SDS sample 
buffer and tau bound to the microtubules was separated from microtubules by SDS – 
PAGE.  Tau samples (0.06-1.0 µg per lane) were loaded on the same gel to generate 
the standard curve.  The SDS-PAGE gels were stained with Commassie brilliant blue 
and scanned with a Hewlett Packard Scanjet 7400 C and imported into Adobe 
Photoshop 7.0.1.  The intensity of standard tau samples were plot versus the amount 
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of tau protein and fit to a linear equation.  The concentrations of tau bound to the 
microtubules were determined by the intensity of tau bands and the standard curve 
obtained from the same gel using the histogram function in Adobe Photoshop 7.0.1.  
The intensity of the tau bands were normalized to the intensity of the tubulin bands in 
each lane to take the differences in centrifugation and/or resuspension of samples into 
account because the concentration of tubulin should be the same in every binding 
sample.  The amount of free tau was determined by subtracting the amount of bound 
tau from the amount of total tau.  The concentration of bound tau was plotted versus 
the concentrations of free tau in GraphPad Prism and the curves were fit to a one site 
binding (hyperbola) equation (101):  
y = Bmax * x/(Kd+x) 
where Bmax is the maximal binding and Kd is the concentration of tau required to 




CHAPTER 4 PSEUDOHYPERPHOSPHORYLATION OF TAU 
MODULATES ITS FUNCTION 
Pseudophosphorylation and pseudohyperphosphorylation mutants were 
generated by the site-directed S/T to E/D substitution on the longest tau isoform 
(ht40).  The changes of tau functions were assayed.  We hypothesized that 
pseudohyperphosphorylation tau mutants will induce a greater change on tau function 
in microtubule binding and aggregation than the pseudophosphorylation mutants at 
single or double sites. 
 
4.1. Result  
4.1.1 Selection and generation of pseudophosphorylation and 
pseudohyperphosphorylation tau mutants 
Tau is abnormally hyperphosphorylated in AD and tauopathies (8, 53).  The 
molar ratio of phosphorylation is increased from 2-3 mol of phosphates per mole of 
tau in normal brain to 5-9 mol of phosphates per mole of tau in AD brain (43, 53).  
However, the role of hyperphosphorylation on AD and tauopathies is not clear.  GSK-
3β can only phosphorylate tau to a ratio of approximately 2-4 mol phosphates per 
mole of tau and this is sufficient to induce tau filament to coalesce into tangle-like 
aggregates similar to those isolated from AD (104, 105).  Due to the low molar ratio 
and heterogeneous characteristics of GSK-3β phosphorylation, 
pseudohyperphosphorylation mutants were generated to study the role of 
hyperphosphorylation at specific sites on tau function.  We chose to focus on the five 
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sites that were phosphorylated by GSK-3β when polymerized tau was used as the 
substrate.  These five sites are S199, T205, T231, S396, and S404 (105).  
Pseudophosphorylation at S202 was added to generate the 6-Phos and 
pseudophosphorylation at both S202 and S235 were added to generate the 7-Phos.  
Phosphorylation at S202 is generally believed to happen together with 
phosphorylation at S199 in AD and can be recognized by antibody AT8; similarly for 
S235 and T231, which can be recognized by antibody TG-3 (13, 43).  Single, double 
and triple mutants were also generated to determine whether similar changes induced 
by pseudohyperphosphorylation can be induced by pseudophosphorylation at fewer 
sites (Figure 4.1A).    The pseudophosphorylation at T212, S208, and S210 in the 
proline rich region were also included in the analysis as controls.  T212 has been 
shown to significantly increase tau aggregation in another report (100).  S208 and 
S210 can be phosphorylated by a non-proline directed protein kinase, tau-tubulin 
kinase (TTK), and are in the same region of tau where most of GSK-3β 
phosphorylation sites are found (37).  The FTDP-17 mutant, P301L, was used as a 
positive control because it has been shown to drastically change tau functions in 
previous reports (164, 165, 173, 175, 196, 197).   
 
4.1.2 Pseudophosphorylation at S199/S202/T205, S396/S404, 6-Phos, and 7-Phos 
induced an SDS-resistant upward band shift. 
Both hyperphosphorylated tau isolated from AD and tau phosphorylated by GSK-3β 












Figure 4.1.   Simulation of tau phosphorylation by glutamic acid or aspartic acid 
replacement.  A) Schematic representation of phosphorylation sites on the longest tau 
isoform.  Four microtubule binding repeats are indicated by light gray boxes (R1 – R4) and 
exon 2, 3 and 10 (E2, E3, and E10) are indicated by dark gray boxes.  Pseudophosphorylation 
sites substituted with glutamic acid or aspartic acid are indicated by the black dots and are 
labeled to the right of the diagram showing their position.  The mutants having 
“pseudohyperphosphorylation” like changes are indicated by asterisks.  The exons are not 
drawn to scale.  B) SDS-resistant conformational changes were observed in the 
“pseudohyperphosphorylation” like mutants (S199/S202/T205E, S396/404E, 6-Phos, and 7-
Phos).  One microgram of each tau protein sample was resolved by SDS-PAGE in a 15% gel.  
C) SDS-resistant conformational changes shown in the “pseudohyperphosphorylation” 
mutants were reduced by 6 M urea.  One microgram of each tau protein sample (wild type, 
S199/S202/T205E, S396/404E, 6-Phos, and 7-Phos) was resolved by SDS-PAGE on a 15% 











was also observed in the pseudophosphorylation mutants with amino acid 
substitutions  at  5  or  10  sites  in  the  proline  rich  region  and/or C-terminal region 
(91, 198).  To determine whether the pseudophosphorylation mutants we generated 
have an AD-like upward band shift as well, all the pseudophosphorylation mutants 
were analyzed by SDS-PAGE followed by commassie stain.   
Only four of these pseudophosphorylation mutants showed an SDS-resistant 
upward band shift (Figure 4.1B).  These mutants were S199/S202/T205E, S396/404E, 
6-Phos, and 7-Phos.  The apparent molecular weights for wild type and these mutants 
determined from SDS – PAGE were 70 kDa, 72 kDa, 75 kDa, 78 kDa, and 78 kDa, 
respectively.    All the other pseudophosphorylation mutants and P301L did not show 
a change in mobility.  These SDS-resistant upward band shifts were drastically 
reduced in the presence of 6 M urea (Figure 4.1C).  The apparent molecular weights 
for wild type, S199/S202/T205E, S396/404E, 6-Phos, and 7-Phos on the SDS-PAGE 
gel with 6 M urea were 70 kDa, 70 kDa, 71 kDa, 72 kDa and 72 kDa, respectively.  
Because these pseudophosphorylation mutants reproduced the SDS-resistant 
conformational change in AD, we concluded that they have the similar characteristics 
as hyperphosphorylated tau.  Therefore, these pseudophosphorylation mutants with 
upward band shift (S199/S202/T205E, S396/404E, 6-Phos, and 7-Phos) are referred 
to pseudohyperphosphorylation mutants hereafter.   
 
4.1.3 Pseudophosphorylation changed tau binding affinity for microtubules. 
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The microtubule binding of tau is negatively regulated by phosphorylation 
(44-46).  A similar decrease in MT binding affinity was also observed in FTDP-17 
mutants (12, 196) and pseudophosphorylation mutants (101).   Therefore, we 
measured the microtubule binding affinity for P301L tau and fifteen 
pseudophosphorylation mutants by a centrifugation assay (199).  Pellets containing 
microtubules and tau bound to MTs were resuspended in 1x SDS-sample buffer and 
resolved by SDS -PAGE (Figure 4.2A).  Tau samples (0.06-1.0 µg per lane) were 
loaded on the same gel (lane 1-5 in Figure 4.2A) to generate a standard curve for tau 
concentration determination.  The intensity of the standard tau samples was plotted 
versus the amount of tau protein and fit to a linear equation (Figure 4.2 B).  The 
intensity of tau bands on SDS-PAGE gels were determined and normalized to the 
intensity of the tubulin band.  The concentrations of bound tau were determined from 
the standard curve using the normalized intensity of the band.  Normalization of the 
tau band to tubulin band was performed to take all the differences during 
centrifugation and resuspension into account.  The amounts of free tau were 
determined by subtracting the amounts of bound tau from the total amounts of tau.  
The concentrations of bound tau were plotted versus the concentrations of free tau 
and the curves were fit to a one-site binding equation.  Two representative curves are 
shown in Figure 4.2C (● wild type; ○ 7-Phos).  The binding affinity (dissociation 
constant, Kd) and the maximal amount of binding (Bmax) were calculated from the 
equation.  The stoichiometry of binding (n) was calculated by dividing Bmax by the 




Figure 4.2. Pseudophosphorylation changed tau – MT binding affinity.  The microtubule 
binding affinity of tau was determined by a centrifugation assay.  A) A representative SDS-
PAGE gel after centrifugation.  Tau standards were loaded in lanes 1-5 with tau 
concentrations at 0.0625, 0.125, 0.25, 0.5, and 1.0 µg, respectively.  Tau protein, 
concentrations varying from 0.125 to 10 µM, was incubated with taxol stabilized 
microtubules at a constant concentration of 1.62 µM tubulin dimers for 30 min at room 
temperature.  The reactions were centrifuged to separate free tau from MT and tau bound to 
MT after incubation.  The bound tau was separated from MT by SDS-PAGE and gels stained 
with Commassie brilliant blue.  B) Representative standard curve.  The intensity of tau 
standard bands was determined from SDS-PAGE and plotted versus the amount of tau protein 
in each band.  The data were fit to a linear regression.  C) Two representative curves of MT 
binding (● wild type, ○ 7-Phos).  The concentrations of bound tau were determined from the 
intensity of tau bands on SDS-PAGE gel and standard curve.  The concentrations of free tau 
were calculated by subtracting the concentration of bound tau from total tau concentration.  
The concentrations of bound tau were plotted versus that of free tau and fit to a one site 
binding equation.  Kd and n (n = Bmax / [tubulin]) for each of three independent repetitions of 
the binding curves were determined from the equation and shown in panels C and D, 
respectively.  All data were presented as the average of three independent repetitions ± s.d. (n 
= 3).  Values that were significantly different from wild type values at P < 0.05 (*) and P < 






concentration of tubulin dimer (1.62 µM).  The values for Kd and n were plotted in 
Figure 4.2D and 4.2E.  All of the pseudophosphorylation mutants examined, with the 
exception of S199E, S202E and T205E, had increased Kd values, which suggested 
they had significantly reduced binding affinity compared with wild type tau (Figure 
4.2D).  The pseudohyperphosphorylated tau mutants (S199/S202/T205E, S396/404E, 
6 -Phos, and 7-Phos) did not show a larger effect compared with single or double 
mutants.  The changes on microtubule binding were all in the 2-3 fold reduction range, 
which was in general agreement with the previous reports on tau phosphorylated by 
GSK-3β (200, 201) and tau phosphorylated within the proline rich region and C- 
terminal region by other kinases (45). The FTDP-17 mutant, P301L, had a lower MT 
binding affinity compared with wild type tau, as shown previously by another group 
(12).  The stoichiometry of tau binding to microtubules was not greatly changed, with 
S202/T205E be the only pseudophosphorylation mutant having an elevated saturation 
level (Figure 4.2E).  In our study, wild type and mutant tau bound to MT at a 
stoichiometry close to 0.5 µM tau per 1.62 µM tubulin dimers, which was roughly 
one tau molecule per 3 tubulin dimers.        
 
4.1.4 Pseudophosphorylation influenced the arachidonic acid induction of tau 
polymerization. 
4.1.4.1 Pseudophosphorylation changed the kinetics of tau polymerization induced by 
arachidonic acid at the optimal arachidonic acid to tau ratio. 
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Tau protein phosphorylated at certain sites has been shown to be prone to 
aggregation. A similarly increased aggregation rate was observed in the 
pseudophosphorylation mutant S396/404E (76).  To determine whether 
pseudophosphorylation mutants of tau have an effect on the kinetics of arachidonic 
acid (ARA) induced tau polymerization, each protein, at a final concentration of 2 µM, 
was incubated with 75 µM ARA.  These concentrations were chosen because this 
concentration of tau was close to the physiological concentration in human brain (202) 
and 75 µM ARA was shown to be the optimal inducer concentration for 2 µM tau in 
our previous study (194).   The kinetics of polymerization for each mutant were 
followed by laser light scattering (LLS) and four representative curves are shown in 
Figure 4.3A.  The curves were fit to a Gompertz function (81, 100).  The maximal 
laser light scattering (LLSmax), the apparent proportional growth rate (Kapp) and lag 
time for each mutant were determined from the equation and shown in Figure 4.3B - 
D.   
None of the pseudophosphorylation mutants had an increased LLSmax (Figure 
4.3B).  Instead, seven of fifteen pseudophosphorylation mutants had a decreased 
amount of polymerization at apparent steady state compared with wild type tau.  
These mutants were S202/T205E, S199/S202/T205E, S208/S210D, T231E, 
S396/S404E, 6-Phos and 7- Phos.  The decreased polymerization was observed in the 
GSK-3β phosphorylated tau in our previous report (104) and the phosphorylation at 
S262 by MARK and S214 by PKA by another group (203).  The FTDP-17 mutant,        
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Figure 4.3. Pseudophosphorylation changed the kinetics of tau polymerization induced 
with arachidonic acid.  Wild type and pseudophosphorylation tau mutants at 2 µM protein 
concentration were incubated with 75 µM ARA in polymerization buffer for 6 hr.  The 
amount of polymerization at regular time intervals was monitored by laser light scattering 
(LLS).   A) Four representative curves of laser light scattering at various time points.  ■ wild 
type; ▲ S199/S202/T205E; ▼ 7-Phos; ♦ P301L.  Each curve was fit to a Gompertz equation.  
Maximal laser light scattering (LLSmax), Kapp and lag time were determined from the equation 
and shown in panels B, C and D, respectively.  All data were presented as the average of 
three independent repetitions ± s.d. (n = 3).  Values that were significantly different from 
wild type values at P < 0.05 (*) and P < 0.01 (**) were determined by one-way ANOVA 
analysis of variance with Dunnett’s multiple comparison post-test using wild type as the 












P301L, was the only mutant that had an increased amount of polymerization 
compared with wild type, which was in agreement with a previous report (67).     The 
apparent proportional growth rate Kapp, which reflected the elongation rate, was not 
significantly changed in most of the pseudophosphorylation mutants (Figure 4.3C).  
P301L had a drastically increased apparent polymerization rate, Kapp, compared with 
wild type,  which agreed with a previous report (67).  The Kapp of P301L was also 
significantly greater than those of all the pseudophosphorylation mutants.  Two of the 
pseudophosphorylation mutants (S210D and T231E) had an increased apparent 
proportional growth rate compared with wild type tau but the changes were much 
smaller compared with that of P301L (Figure 4.3C).  The pseudohyperphosphorylated 
forms of tau (S199/S202/T205, 6-Phos, and 7-Phos) had a significantly lower Kapp as 
shown in Figure 4.3C.        
The ARA induced tau fibrillization has been shown to be a “nucleation-
elongation” process (77, 204) which was reflected by the presence of a lag time.  The 
nucleation rate has been suggested to be modified by phosphorylation (205).  In our 
study, the decreased lag time was observed in four of the pseudophosphorylation 
mutants (S210D, S208/S210D, T231E, and T231E/S235D) and P301L compared to 
wild type tau (Figure 4.3D).  However, none of these pseudophosphorylation mutants 
was able to reduce the time for nucleation to the same level as P301L did.   A 
significantly increased lag time was observed in the polymerization reaction of 6-
Phos, which suggested a defect in nucleation.  The lag times of the S199/S202/T205E 
and 7 -Phos mutants were comparable to those of the wild type (Figure 4.3D). 
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4.1.4.2 Pseudophosphorylation changed the morphology of tau filaments induced by 
arachidonic acid at the optimal arachidonic acid to tau ratio. 
To determine whether pseudophosphorylation changed the morphology 
(number and length) of the filaments, the polymerization reactions were prepared and 
viewed by TEM.  Representative images are shown in Figure 4.4. 
In general, there were fewer but longer filaments formed by 
pseudophosphorylation mutants compared with wild type tau.  In contrast, P301L 
formed more and shorter filaments.  This observation was confirmed by quantitative 
analysis of the filaments (Figure 4.5).    The images were analyzed using Optimas 
image analysis program and the length for each filament was determined.  Only 
particles longer than 15 nm were counted.  This cutoff value is the average width of 
the filaments induced by arachidonic acid and particles shorter than this value are 
difficult to distinguish from the background.  The filaments from all six images were 
put into one data set and plotted in Figure 4.5.  The general trend of forming fewer 
but longer filaments was observed in most of the pseudophosphorylation mutants 
(Figure 4.5B and 4.5C).  However, the overall filament length in all six fields of most 
pseudophosphorylation mutants was close to that of the wild type tau, with T231E, 
S202/T205E, T205E and S396/S404E being the possible exceptions (Figure 4.5D).  
The pseudohyperphosphorylated forms of tau (S199/S202/T205E, 6-Phos, and 7-Phos) 
formed the longest filaments and the one with longest average filament length was the 
one with the most pseudophosphorylation sites (7-Phos).  The rapidly polymerizing 





Figure 4.4. TEM analysis of polymerization at a final concentration of 2 µM tau and 75 
µM arachidonic acid.   The polymerization reactions of wild type or pseudophosphorylation 
mutant tau at a final concentration of 2 µM were incubated with 75 µM ARA inducer at room 
temperature for 20 hr.  The reactions were viewed by TEM and representative micrographs 
are shown.  A) wild type, B) S199E, C) S202E, D) T205E, E) S202/T205E, F) 
S199/S202/T205E, G) S208D, H) S210D, I) S208/S210D, J) T212E, K) T231E, L) S235D, 
M) T231E/S235D, N) S396/S404E, O) 6-Phos, P) 7-Phos and Q) P301L.  Scale bar in Q) 



























Figure 4.5.  Filament distribution of polymerization reactions at a final concentration of 
2 µM tau protein and 75 µM arachidonic acid inducer.  The polymerization reactions of 2 
µM wild type tau and pseudophosphorylation mutant tau induced by 75 µM ARA were 
viewed by TEM after 20 hr incubation at room temperature.  Resulting filament lengths were 
analyzed by Optimas image analysis program.  Six 6 х 6 µm fields were analyzed for each 
protein.  Only the filaments longer than 15 nm were counted.  A) The filament lengths from 
all six fields were combined into a single data set and ranked from the shortest to the longest.  
Each individual filament was plotted against its corresponding rank for each protein.  Eight 
samples were shown and each sample was individually colored and labeled on the graph.  
The distributions for S210D, S208/S210D, T231E/S235D and S396/S404E were similar to 
that of T205E.  The distributions for S202T/205E, S208D and S235D were similar to that of 
S202E.  The distributions for T212E and T231E were similar to S199E.  B) The total number 
of filaments observed in all six fields for each protein is shown and ranked from the one with 
the least filaments to the one with most.  Each bar was individually labeled on the graph.  C) 
The average length of the filaments observed in all six fields for each protein is shown and 
ranked from the one with the shortest average filament length to the one with the longest.  
Each bar is individually labeled on the graph.  Values are shown as average ± s.d. (error bars 
above only) and ± s.e.m. (bar above and below) (n=6).  D)  The sum of filament lengths of all 
the filaments observed from all six fields for each protein is shown and ranked from the one 
with least total filament mass to the one with greatest.  Each bar is individually labeled on the 
graph.  In general, fewer but longer filaments were observed in pseudophosphorylation 








Figure 4.6. Pseudophosphorylation mutant tau forms longer filaments than wild type 
tau.  Wild type tau and pseudophosphorylated mutant tau at 2 µM protein concentration were 
incubated with 75 µM ARA in polymerization buffer at room temperature for 20 hr.  
Resulting filament lengths of 500 filaments were measured by Optimas image analysis 
program.  The number-average filament length ± s.d. (error bars above only) and ± s.e.m. 
(error bars above and below) for each protein was shown and ranked from the one with 
longest average filament length to the one with the shortest.  Each bar was individually 





in an overall increase in the total filament length from all six fields.  Both the 
standard deviation and standard error of the mean for the average filament lengths are 
shown in Figure 4.5C.  The standard deviation was approximately equal to the value 
of the average filament length for most proteins, suggesting the filaments were in an 
exponential distribution (206).  The standard error of the mean was the estimation of 
the accuracy of the determination of the true mean.  Due to the differences in the 
number of filaments, the variability in filaments distribution on the TEM grids, the 
biological variability in filament lengths, and the exponential distribution of filament 
lengths, the statistical analysis of differences between   the   filaments   is   difficult.    
Therefore, it is possible that the apparent differences in filament distribution shown in 
Figure 4.5 could come from differences in sampling.  To test this possibility, we 
measured 500 filaments for each protein and determined the number-average length 
(Ln=(ΣNiLi)/(ΣNi), Figure 4.6) for each protein.  All the pseudophosphorylation 
mutants formed longer filaments than wild type tau, with T231E to be the lone 
exception (Figure 4.6).  The number-average filament length of P301L was shorter 
than wild type as seen in Figure 4.5C.  This analysis also confirmed that 
pseudohyperphosphorylated forms of tau (S199/S202/T205E, 6-Phos, and 7-Phos) 
formed longer filaments than wild type tau. 
 
4.1.4.3 Pseudophosphorylation mutants responded differently to the changes in tau: 
ARA ratios. 
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The maximal amount of polymerization was not significantly increased in any 
of the pseudophosphorylation mutants (Figure 4.3).  However, in a previously 
published report, a 2-3 fold increase in the amount of polymerization induced by 
arachidonic acid was observed in some of the pseudophosphorylation mutants.  These 
pseudophosphorylation mutants included T212E and S199/S202/T205E, which did 
not show a significant increase in our studies (100).  We previously showed that the 
amount of polymerization induced by arachidonic acid depended both on tau 
concentration and the inducer concentration and there was an optimal inducer to 
protein ratio (194).  Below the optimal inducer to protein ratio, the inducer limits the 
polymerization reactions, and above the optimal induce to protein ratio, the inducer 
inhibits the reaction (194).   The concentration of tau is difficult to determine and the 
difference between the protein concentrations determined by different protein assays 
could be as high as 5-fold (101, 207).  For this reason, we hypothesized that the 
difference between our study and the previous report was due to performing 
experiments at different inducer to protein ratios.  Therefore, we kept the protein 
concentration of tau constant at 2 µM (determined by bicinchoninic acid (BCA) assay) 
and varied the concentrations of ARA from 25 µM to 150 µM.  The resulting 
polymerization was assayed by LLS (Figure 4.7) and ThS (Figure 4.8).  None of the 
mutants had a significantly increased polymerization at the optimal inducer to protein 
ratio as assayed by LLS and ThS (Figure 4.7 and 4.8).  The 2-3 fold increase in 
polymerization was observed in some of the pseudophosphorylation mutants at the 
high inducer to protein ratios (ARA concentration ≥ 125 µM), such as 
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S199/S202/T205E, S210D, S208/S210D and T231E/S235D, when assayed by LLS 
(Figure 4.7).  This result suggested that the increase of polymerization observed in 
some of the pseudophosphorylation mutants was due to the diminution of the 
inhibitory effects at high inducer concentrations on polymerization.  The amount of 
polymerization of P301L was significantly higher than wild type tau at all these 
inducer to protein ratios (Figure 4.7).  The results determined by ThS fluorescence 
generally agreed with the results determined by LLS (Figure 4.8).  All of tau variants 
showed a biphasic dependence on inducer concentrations.  The increase in ThS signal 
was only observed at high inducer concentrations (≥ 125 µM) for some of the 
pseudophosphorylation mutants, including S199/S202/T205E, S210D, S208/S210D 
and T231E/S235D.  However, in some of the mutants, the changes on the amount of 
polymerization were drastically different when using different assays (LLS or ThS).  
These mutants were: S396/404E, 6-Phos, 7-Phos and P301L.  For S396/404E, 6- Phos 
and 7-Phos, the significant increase in polymerization at high inducer concentrations 
was not observed by LLS but observed by ThS.  Because S396/404E, 6-Phos and 7-
Phos were the three mutants that had a mobility change on SDS-PAGE, the change 
induced by pseudophosphorylation may change the binding of ThS with tau filaments 
and result in the changes in ThS fluorescence intensity.  For P301L, the significant 
increase was only observed at the lowest protein concentration.  This could be due to 
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Figure 4.7. Polymerization reactions of pseudophosphorylation tau mutants at final 
concentration of 2 µM protein with various concentrations of ARA inducer were 
assayed by laser light scattering.  Wild type and mutant tau protein (2 µM) were incubated 
in polymerization buffer with ARA at final concentrations varying from 25 µM to 150 µM at 
room temperature for 20 hr.  The amount of polymerization was assayed by laser light 
scattering and shown.  Each protein was individually labeled on each graph.  For ease of 
comparison, the values for wild type tau were included on each graph (light gray curve).  All 
data were presented as average values ± s.d. (n = 3).  Values that were significantly greater 
than wild type values at P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were determined by 
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Figure 4.8. Polymerization reactions of pseudophosphorylation tau mutants at final 
concentration of 2 µM protein with various concentrations of ARA inducer were 
assayed by ThS fluorescence.  Wild type and mutant tau protein (2 µM) were incubated in 
polymerization buffer with ARA at final concentrations varying from 25 µM to 150 µM at 
room temperature for 20 hr.  The amount of polymerization was assayed by Thioflavine S 
fluorescence and shown.  Each protein was individually labeled on each graph.  For ease of 
comparison, the values for wild type tau were included on each graph (light gray curve).  All 
data are presented as average values ± s.d. (n = 3).  Values significantly greater than wild 
type values at P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were determined by a student’s 














4.1.5 Pseudophosphorylation mixtures produced tangle-like aggregates similar to 
those induced by GSK-3β phosphorylation. 
The phosphorylation of tau by GSK-3β either prior to or following 
polymerization promotes the formation of tangle-like aggregates from ARA induced 
individual filaments (104, 105).  These tangle-like aggregates have similar 
morphology and density to those isolated from AD brain (104).  However, these 
tangle-like aggregates were not observed in the ARA induced polymerization 
reactions of the pseudohyperphosphorylated forms of tau (S199/S202/T205E, 6-Phos 
and 7-Phos, Figure 4.4).  Because there are about 2-4 mol phosphate per mole of tau 
after GSK-3β phosphorylation and the phosphorylation is heterogenous (104, 201), it 
is not surprising the tangle-like aggregates from homogenous 
pseudohyperphosphorylation were not observed.    Therefore, to mimic the GSK-3β 
phosphorylation of tau, we mixed equal amounts (0.33 µM) of six different 
pseudophosphorylation mutants (S199E, S202/T205E, S208D, T212E, T231E/S235D 
and S396/S404E), and made the final tau concentration 2 µM.  Each 
pseudophosphorylation mutant in the mixture had 1 or 2 mol “phosphates” per mole 
of tau and the stoichiometry of “phosphorylation” for the mixture was 1.5 mol 
“phosphates” per mole of tau.  The polymerization reactions were induced with 25 
µM or 75 µM ARA and viewed under TEM.  We added 0.3 mM MgCl2, 0.2 mM ATP 
and 20 µM ThS, into the polymerization buffer to mimic the polymerization 
conditions for GSK-3β phosphorylated tau.  The representative TEM micrographs are 
shown in Figure 4.9.  Small clusters were observed in the polymerization reactions 
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for both wild type tau and the pseudophosphorylation mixture (asterisks in Figure 
3.9). 
We also checked the polymerization reactions of wild type tau and the 
pseudophosphorylation mixture induced with 25 µM or 75 µM ARA without the 
additional buffer components and these small clusters were not formed under any of 
these conditions.  This suggested that one or more of these buffer components could 
induce the clustering of filaments into these small aggregates.  The large clusters 
similar to those found in the polymerization reactions of GSK-3β phosphorylated tau, 
were only observed in the polymerization reactions of pseudophosphorylation 
mixture induced with 75 µM ARA (arrow head in Figure 4.9D).  However, even 
though the size of the clusters formed under this condition was close to the clusters 
from GSK-3β phosphorylated tau, they were significantly lower in numbers.   
 
4.2. Discussion 
4.2.1 Significance of pseudophosphorylation mutant sites 
The presence of abnormally hyperphosphorylated insoluble tau in brain is a 
prominent characteristic of AD and other tauopathies.  The phosphorylation level is at 
least 3 to 4 times higher in AD tau than in normal tau (43, 208).  However, it is not 
clear which kinase(s) are responsible for the changes in tau phosphorylation levels.  
There are at least 20 kinases contributing to the phosphorylation of tau.  Among these 
kinases, GSK - 3β is the most attractive candidate for the phosphorylation of PHF tau, 



















Figure 4.9. Formation of tangle-like aggregates from the mixtures of 
pseudophosphorylation tau mutants.  Polymerization reactions of wild type tau and the 
mixtures of pseudophosphorylation tau mutants were incubated with 25 or 75 µM ARA in 
polymerization buffer plus 0.3 mM MgCl2, 0.2 mM ATP, and 20 µM ThS at 30 ºC for 20 hr 
and viewed by TEM.  The protein concentration for wild type tau was 2 µM.  The 
pseudophosphorylation mutant mixtures were composed of S199E, S202/T205E, S208D, 
T212E, T231E/S235D, and S396/404E each at a final concentration of 0.33 µM.  A) wild 
type tau + 25 µM ARA, B) pseudophosphorylation mix + 25 µM ARA, C) wild type tau + 75 
µM ARA, D) pseudophosphorylation mix + 75 µM ARA.  Images were recorded at a 
magnification of 20,000 х.  The scale bar on panel D represents 500 nm and is applicable to 














previous results, GSK-3β can phosphorylate tau at 11 sites when using monomeric 
tau as substrate (104).  These phosphorylation sites are: S199, T205, T212, S214, 
T217, T231, S356, S396, S400, S404, and S409.  Only 5 of these 11 sites can be 
phosphorylated by GSK-3β when using aggregated tau as substrate and 
phosphorylation at these five sites is sufficient to induce tau filaments to coalesce into 
NFT-like aggregates.  These five sites are S199, T205, T231, S396 and S404 (105).  
The previous reports have suggested that all these five of these sites were important 
for the pathological changes of tau.  S199 and T205, together with S202 are the 
epitopes of an AD specific antibody AT8 (209, 210). The pseudophosphorylation at 
these 3 sites has been shown to open up the hairpin conformation of tau and therefore 
may change its ability to aggregate and to bind microtubules and promote their 
assembly (103).  The phosphorylation at T231 occurs in PHF tau and can be 
recognized by a phosphorylation dependent antibody AT180 (211) and by a 
conformation dependent antibody TG-3 together with the phosphorylation at S235 
(212).  T231 has been suggested to be the primary phosphorylation site for GSK-3β 
(213) and the de-phosphorylation at this position in the presence of prolyl isomerase, 
Pin 1, can restore its ability to bind MT (214).   Tau phosphorylated at S396 and S404 
accumulates in late-stage AD and is recognized by monocolonal antibody PHF-1 
(215).   The phosphorylation at these two sites opens up the hairpin conformation of 
tau  (103) and increases the rate of tau aggregation by altering the inhibitory effect of 
the C-terminal region on aggregation (76).   
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4.2.2 Role of phosphorylation in tau aggregation 
The findings that the pattern of tau phosphorylation correlates with the 
amount of NFTs and severity of neuropathology suggest that there is a direct 
correlation between tau phosphorylation and its aggregation (216).  Under the optimal 
polymerization condition we used in our studies, the amount of polymerization was 
not significantly increased in these pseudophosphorylation mutants when assayed by 
laser light scattering.  Instead, in some of the pseudophosphorylation mutants, a 
slightly reduced polymerization was observed.  In general, the filaments formed from 
most of the single and double mutants were fewer in number and greater in length 
(Figure 4.4).  Only slight changes in polymerization kinetics were observed for most 
of these single and double mutants.  However, significantly decreased elongation 
rates were observed in the pseudohyperphosphorylated tau variants 
(S199/S202/T205E, 6-Phos, and 7-Phos).  At the same time, these tau variants had 
longer lag time compared with wild type tau.  The changes in kinetics of these 
pseudohyperphosphorylated tau mutants were in agreement with the changes to tau 
filament morphology.  Longer but fewer filaments were observed in these three 
mutants and this suggested an impaired nucleation process.   
The polymerization condition we used to assay the changes on kinetics and 
polymerization is the optimal condition for polymerization.  Under the optimal 
condition, a large percentage of tau will form filaments.  At lower inducer 
concentrations, the inducer will limit the reaction.  And at higher inducer 
concentrations, the polymerization can be inhibited by the inducer (194).  Although, 
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the pseudophosphorylation mutants did not change the amount of polymerization at 
the optimal inducer concentration, the amount of polymerization may be different 
from wild type tau at other inducer concentrations.  A 2-3 fold increase in 
polymerization was observed at higher inducer concentrations in some of the 
pseudophosphorylation mutants including S199/S202/T205E, S210D, S208/S210D, 
S396/S404E, 6-Phos and 7-Phos by LLS and/or ThS fluorescence (Figure 4.7 and 
Figure 4.8).  This suggested high inducer concentrations inhibited polymerization to a 
lesser extent than wild type tau in some pseudophosphorylation mutants.   
Arachidonic acid has been known to induce tau polymerization by decreasing 
the energetic barrier for the nucleation of polymerization (194).  Although no direct 
evidence has been shown, the induction process may involve the direct binding 
between tau and ARA.  The decreased nucleation process suggested by kinetics and 
filament morphology together with the decreased inhibitor effects at higher inducer 
concentrations may be caused by the diminished interactions between ARA and tau.   
This idea was supported by the observed mobility changes on SDS-PAGE (Figure 
4.1).  The different results between LLS and ThS observed on S396/404E, 6-Phos, 
and 7-Phos may also be due to the altered interactions between tau and ThS resulting 
from conformational changes. 
 
4.2.3 Role of phosphorylation in microtubule binding  
The phosphorylation at the region outside of the MT binding repeats usually 
results in a 2-3 fold decrease in the tau-MT binding affinity (47).  A similar 2-3 fold 
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decrease was observed in most of our pseudophosphorylation mutants without 
significantly changing the saturation levels of binding.  An interesting aspect of the 
changes in MT binding is that these changes are not additive.  For example, both 
T231E and S235D had a lower MT-binding affinity compared with wild type tau.  
However, no further decrease was observed in the MT-binding affinity of 
T231E/S235D double mutant.  Similarly, the S202/T205E double mutant had a 
significantly decreased MT-binding.  However, instead of causing a decrease, the 
additional mutation at S199 increased the MT-binding affinity (albeit still more lowly 
than wild type tau).  This observation suggests that the effect of phosphorylation on 
MT-binding does not depend on the number of phosphorylation sites.  Rather, the 
regulation of MT-binding is through a more complicated site specific manner. 
 
4.2.4 Comparison with phosphorylation by GSK-3β 
Pseudophosphorylation has been used to study the contribution of the 
phosphorylation at specific sites on tau functions.  The results from this study showed 
that pseudophosphorylation reproduced the changes induced by GSK-3β in many 
aspects.  The SDS-resistant conformational change similar to that induced by GSK- 
3β phosphorylation was observed in four of our pseudophosphorylation mutants (104, 
201).  The reduction of tau-MT binding affinity was approximately 2-3 fold and was 
similar to the mild reduction induced by GSK-3β phosphorylation (217).  GSK-3β 
phosphorylation had a slightly decreased polymerization compared to wild type tau 
which was reproduced by our pseudophosphorylation mutants.  However, the tangle-
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like aggregates induced by GSK-3β were not formed in any of the 
pseudophosphorylation mutants, not even in the pseudohyperphosphorylation mutants.  
Similar aggregates, but drastically few in number, were observed in the mixture of 
some of these pseudophosphorylation mutants.  One difference between 
pseudohyperphosphorylation mutants and the mixture of pseudophosphorylation 
mutants is the ratio of “phosphate” to tau.  The ratio of 1.5 mol phosphates per mole 
of tau in the mixture of pseudophosphorylation mutants is closer to the 2-4 mol 
phosphate in the GSK-3β phosphorylated tau (104, 201). In addition, the mixture of 
pseudophosphorylation mutants reproduced the heterogenous phosphorylation 
induced by GSK-3β better than the homogenous pseudohyperphosphorylation.   
Therefore pseudophosphorylation mimics phosphorylation induced by GSK-3β to a 
certain degree, but does not completely model the full effects of phosphorylation. 
 
4.2.5 Phosphorylation, polymerization, NFTs formation and neurotoxicity 
NFTs are one of the diagnostic hallmarks of AD and the number of NFTs 
correlates with the degree of dementia (8).  Therefore, NFTs have been considered as 
the toxic species in AD for a long time.  However, increasing evidence from tau-
expressing cultured cells, transgenic C. elegans models, transgenic Drosophila 
models and transgenic mouse models suggest that NFTs are not required for 
neurotoxicity (1.5.1).  The hyperphosphorylation of tau resulting from the constitutive 
activation of cdk5 in primary neurons and pseudohyperphosphorylated tau expressed 
in PC12 cells were sufficient to promote cell death without the presence of detectable 
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protein aggregates (118).  The neuronal dysfunction and neuronal loss were observed 
without or before the presence of  NFTs in Tg C. elegans, Tg Drosophila and Tg 
mice (142, 146, 160-162).  Although NFTs and tau filaments were not observed in 
these models, hyperphosphorylation and the resulting conformational changes are 
required for the toxicity.  The evidence for this came from the fact that tau isolated 
from NFTs and these animals was hyperphosphorylated and had an SDS-resistant 
mobility change (142, 146, 160-162).  In addition, the presence of soluble 
hyperphosphorylated tau correlates with the cognitive deficiencies in a Tg mouse 
model (166).  The toxicity of hyperphosphorylated tau was due to the disruption of 
the cytoskeleton.  The hyperphosphorylated tau with the conformational change can 
be released from MT and was able to sequester the normal tau, and therefore 
disrupted the MT network and resulted in cell death.  The toxicity of 
hyperphosphorylated tau could be reduced by the formation of filaments and 
consequent formation of NFTs.  Therefore, hyperphosphorylated tau monomers 
and/or oligmers could be the toxic species and tau filaments and NFTs may work as a 
result of cellular attempts to reduce toxicity.   
Our results provide a possible mechanism for the potential toxicity of 
hyperphosphorylated tau in neurons.  The hyperphosphorylated tau with lower MT 
binding affinity will be released from MT.  Therefore, the concentration of cytosolic 
hyperphosphorylated tau, which is most likely to be the toxic species, will be 
increased.  This will result in two changes: 1) the soluble hyperphosphorylated tau 
will sequester normal tau and further de-stabilize microtubules; 2) the soluble 
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hyperphosphorylated tau at high concentrations will start to coalesce into filaments.  
However, the hyperphosphorylated tau has slower kinetics of aggregation compared 
with wild type tau and the hyperphosphorylated tau will stay in the toxic soluble form 
for a longer time.  The toxic hyperphosphorylated tau may finally be removed by the 
formation of less toxic filaments.  These filaments can further coalesce into 
neurofibrillary tangles which have been observed from GSK-3β phosphorylated tau 




























CHAPTER 5: CONCLUSIONS AND IMPLICATIONS 
 
My dissertation work focused on the effects of hyperphosphorylation on tau 
functions.  This work contributes to the understanding of tau toxicity in the 
progression of AD and other tauopathies. 
 
5.1 Tau toxicity 
Although much progress has been made in the study of tau protein, it is still 
not clear how tau dysfunction contributes to toxicity and neurodegeneration in 
tauopathies.  Both the loss of normal tau function and the gain of toxic function are 
believed to play a role in inducing neuronal dysfunction and dementia.  
 
5.1.1 The loss of normal tau function 
The major function of tau in neurons is to bind and stabilize microtubules and 
to promote microtubule assembly (reviewed in (8)).  Both missense mutations in 
FTDP-17 and hyperphosphorylated tau in sporadic AD have reduced abilities for 
regulating microtubule stability and dynamics (reviewed in (8, 13, 30, 32)).  Because 
4R isoforms and 3R isoforms have different binding affinities for microtubules, the 
changes of 3R to 4R ratios in some of the mutations linked to FTDP-17 also alter tau 
function of binding microtubules (reviewed in (32)).  The reduced ability of tau to 
regulate microtubule stability and dynamics and the missorting of tau into 
somatodendrites will disrupt the microtubule in axons (205).  Therefore neurons will 
lose the tracks for axonal transport, resulting in synaptic damage.  Axonal dysfunction 
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and synaptic damage were observed in early stages of AD (218) and were mimicked 
in a transgenic Drosophila model (219) and transgenic mouse models (172, 220).    
However, the results from tau knock-out mice suggested the loss of normal 
function alone was subtle and was not sufficient to induce neurodegeneration.  In tau 
knock-out mice, axonal elongation and axonal transport rates were normal and no 
sign of cytoskeletal collapse was observed in these mice (157, 221).  This observation 
may be due to the present of redundant microtubule associated proteins such as 
MAP1 and MAP2 in neurons (157).  Therefore, other mechanisms must be present 
and contribute to tau toxicity. 
 
5.1.2 The gain of toxic function  
The gain of toxic function of tau was first suggested by the close correlation 
between the number of NFTs and the severity of cognitive decline in AD (18).  The 
early onset dementia in FTDP-17 further strengthens the correlation between tau 
dysfunction and dementia (32).  However, the dissociation of NFTs with 
neurotoxicity in transgenic (Tg) C. elegans, Tg Drosophila and Tg mouse models 
suggests NFTs are not required for neurotoxicity (reviewed in (222)).  Instead, 
hyperphosphorylated tau monomers or intermediates of tau polymerization, including 
oligomers and protofibrils, might be the species causing neurotoxicity (223, 224).  
The abnormally hyperphosphorylated tau can sequester normal tau from microtubules 
(61) and this can result in the disruption of microtubule networks and the loss of 
synapses (205, 225).  Hyperphosphorylated tau has a reduced ability in recruiting 
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normal tau after it aggregates into filaments (226).  Therefore,  hyperphosphorylated 
monomeric tau or tau oligomers are the toxic species, and PHFs and NFTs are 
possibly the end products of cellular attempts to remove the toxic species (reviewed 
in (227)).  Although there is no report of FTDP-17 mutations resulting in 
sequesteration of  normal tau, these mutant taus are better substrates for kinases, and 
may therefore be more toxic than wild type tau due to increased phosphorylation (64).  
In support of this, Tg mice expressing FTDP-17 mutations always have more severe 
neurotoxic pathologies than wild-type tau, and human tau expressed in these mice is 
always hyperphosphorylated (reviewed in (222)). 
Although the MT inhibitory effects can be removed when 
hyperphosphorylated tau forms PHFs and NFTs, NFTs can still affect the normal 
function of neurons.  NFTs can serve as a physical barrier and compromise normal 
cell functions.  The accumulation of NFTs takes up space in cells and pushes away 
the cytoplasmic organelles from their normal positions.  The mislocated organelles, as 
well as a decreased number of cytoplasmic organelles were observed in Tg mice 
expressing P301L tau (165).  In addition, NFTs can physically block the movement of 
organelles (such as mitochondria) along microtubules or trigger the release of cargo 
from kinesin (228, 229).    
Our results contribute to the hypothesis of “the loss of normal function and the 
gain of toxic function” in several aspects.  First, reduced MT binding affinity was 
observed in pseudohyperphosphorylation tau mutants.  And this is in agreement with 
the hypothesis of the loss of normal function.  Second, pseudohyperphosphorylation 
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tau mutants have increased lag times for polymerization which keeps these tau 
mutants in monomer or oligomer forms for longer periods of time.  Because evidence 
suggests monomers and oligomers are the toxic species for cells, this could explain 
the higher toxicity for hyperphosphorylated tau.  The toxicity can be removed by 
aggregating into filaments and NFTs.   
 
5.2 What triggers the hyperphosphorylation of tau? 
 
The abnormal hyperphosphorylation of tau is the result of an imbalance 
between protein phosphorylation and de-phosphorylation.  Many kinases and 
phosphatases are believed to be involved in this process (reviewed in (230)).  
However, it is not clear what kind of changes in brain trigger the upregulation of 
kinases and downregulation of phosphatases.  Considering the different phenotypes in 
different tauopathies, there must be more than one pathway involved.  Therefore, the 
combination of these pathways in different subgroups of tauopathies results in the 
different disease phenotypes.  Several hypotheses have been suggested based on the 
results from in vivo or in vitro experiments. 
 
5.2.1 Aβ hypothesis 
Aβ peptide is the proteolytic product of Aβ precursor protein (APP) (reviewed 
in (231, 232)).  Because mutations in APP can cause the early onset familial AD with 
all the typical neuropathologies of AD (reviewed in (231, 232)), Aβ was believed to 
be the factor inducing tau phosphorylation and aggregation.  Extracellular soluble Aβ 
was suggested to bind to receptors on the cell membrane and activate intracellular 
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kinases such as GSK-3β and increase the phosphorylation levels of tau (233).  The 
increased amount of fibrillar Aβ can also induce oxidative stress in cells and produce 
reactive oxygen species (reviewed in (231)).  Intracellular reactive oxygen species 
can active kinases (such as JNK and MAPK) and induce the hyperphosphorylation of 
tau (reviewed in (231)). 
The effects of Aβ peptides on tau phosphorylation have been demonstrated in 
transgenic mouse models.  NFTs composed of hyperphosphorylated tau were 
observed in Tg mice expressing an AD-associated APP mutation (190) and P301L tau, 
and in P301L Tg mice after microinjection of Aβ fibrils into the brain  (193).  
However, the Aβ hypothesis can not explain the occurrence of tau 
hyperphosphorylation in other tauopathies which are free of Aβ pathology. 
 
5.2.2 Oxidative stress hypothesis 
The involvement of oxidative stress in AD and other neurodegenerative 
diseases have been suggested in many reports (reviewed in (234)).  Heavy metals, as 
the potential sources of free radicals have been found to colocalize with NFTs in AD 
( reviewed in (234)) and Aβ filaments can promote tau phosphorylation through the 
generation of reactive oxygen species as mentioned above.  The following 
aggregation of hyperphosphorylated tau can remove the free radicals and therefore 
this is believed to be a protective response to the toxic oxygen species. 
 
5.2.3 Impaired glucose metabolism hypothesis 
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In addition to phosphorylation, tau also undergoes other posttranslational 
modifications, such as glycosylation.  There is a different glycosylation, O-GlcN-
acylation, for neuronal phosphoproteins such as tau (235).  O-GlcN-acylation is the 
modification of adding a single sugar at serine or threonine residues, which are 
potential sites for phosphorylation.  Therefore, the reduction of O-GlcN-acylation 
results in the increase of phosphorylation (reviewed in (230)).  The regulation of O- 
GlcN-acylation is directly related to the glucose uptake/metabolism and the impaired 
glucose metabolism in AD brain can increase tau phosphorylation through decreased 
O-GlcN-acylation (reviewed in (230)). 
 
5.2.4 Other factors 
There are other less general factors that are involved in promoting tau 
phosphorylation in AD and other tauopathies.  Several FTDP-17 mutants are more 
favorable substrates for kinases and therefore can be phosphorylated more easily than 
wild type tau (reviewed in (16)).  The presence of one or two APOE4 alleles increases 
tau phosphorylation through indirect regulation of GSK3 in AD (reviewed in (232)).  
The wnt signaling pathway can upregulate tau phosphorylation by increasing GSK3 
activity and/or increasing Aβ aggregation (reviewed in (232)).  
 
The progression of AD is a complicated process.  There are still many 
unsolved issues in this puzzle.  A schematic showing the proposed major steps in the 
tau contribution to AD is listed in Figure 5.1. 
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Figure 5.1.  A schematic showing the proposed major steps in the progression of 



















5.3 Future directions 
 
To test the hypothesis about hyperphosphorylated tau toxicity, a cell model 
expressing pseudohyperphosphorylated tau mutant (7-Phos) will be built.  The 
following changes could be assayed in cultured cells:  kinase/phosphatase activities, 
the phosphorylation states of tau at other sites, the intracellular distribution of tau, the 
amounts of sarkosyl soluble tau and other microtubule associate proteins (MAP1 and 
MAP2), the amount and morphology of sarkosyl insoluble tau, and microtubule 
dynamics.  These changes will be analyzed together with the changes in cell viability, 
cell morphology and cell function.  The relation between the changes in tau function 
and cell viability/function could reveal the potential mechanism of 
hyperphosphorylated tau toxicity.   
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APPENDIX CHAPTER: IN VITRO TAU POLYMERIZATION IS 
INFLUENCED BY THE MOLECULAR NATURE OF THE 
INDUCER AND THE VOLUME OF THE REACTION. 
 
App.1 Rationale and aims 
 
The microtubule associated protein tau is hyperphosphorylated in AD and 
other tauopathies (reviewed in (8)).  Hyperphosphorylated tau can spontaneously self-
aggregate into paired helical filaments (PHFs) and straight filaments (SFs).  PHFs and 
SFs can further coalesce into neurofibrillary tangles (NFTs), which are correlated 
with the type and severity of dementia in AD (reviewed in (69, 236)).  However, 
recombinant human tau does not spontaneously aggregate under physiological 
conditions and inducer molecules are required to initiate the aggregation of tau in 
vitro (reviewed in (75, 237)).  To date, the known inducer molecules are polyanionic 
compounds such as heparin (238), polyglutamate (79), RNA (80) and fatty acids (81).  
Arachidonic acid (ARA) is one of these inducer molecules.  However, the mechanism 
of ARA induced tau aggregation is not understood.  ARA contains a single charge at 
its carboxyl group and a long hydrophobic tail.  It has a high tendency to form 
polyanionic micelles in aqueous solutions and has been suggested to promote the 
initiation of tau polymerization in the form of micelles (84).  In support of this 
hypothesis, a decreased critical micelle concentration (CMC) of ARA was observed 
in the presence of tau as assayed by N-phenyl-1-napthylamine (NPN) and individual 
ARA molecules were not found to be associated with tau filaments (204).  In addition, 
 97
the polymerization of tau can be induced by lipid vesicles and carboxylate-conjugated 
polystyrene microspheres, which are similar to ARA micelles in the aspect of 
structure and charge distribution (204, 239).  All these data suggested that the 
formation of micelles is a prerequisite for the ARA-induced tau aggregation.   
However, the results from other experiments questioned this hypothesis.  First, 
ARA micelle formation was not observed in the presence of an assembly incompetent 
form of tau when assayed by laser light scattering (240).  Meanwhile, micelle 
formation of an alkyl sulfate detergent was easily detected under the same condition 
by laser light scattering (240).  Second, the critical micelle concentration of ARA was 
drastically different when determined by laser light scattering and N-phenyl-1-
napthylamine (204, 241).  The difference may come from the direct binding between 
tau and N-phenyl-1-napthylamine which has been suggested to bind directly to 
certain proteins having high affinity for aldehydes or fatty acids (242).  Or this 
difference might be due to the size of micelles forming in the presence of tau being 
too small to be detected by laser light scattering.  Third, although tau filaments were 
observed by the induction of carboxylate-conjugated polystyrene microspheres, the 
length distribution of these filaments is significantly different from these induced by 
ARA (204, 239).  This evidence suggests that ARA can induce tau polymerization 
through different mechanisms and the molecular nature of ARA can affect the 
morphology of tau filaments. 
The aim of this study is to determine the relationship between the molecular 
nature of ARA with filament morphology induced by ARA and to determine the 
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mechanism of ARA induced tau polymerization.  To address this, divalent cations at 
different final concentrations were added to the reaction buffer to alter ARA micelle 
formation and the filaments formed under different conditions were assayed and 
compared with the filaments induced by carboxylate-conjugated polystyrene 
microspheres.  The surface area : volume ratio was also found to influence tau 
polymerization induced by ARA.  Therefore, the polymerization reactions induced by 
ARA in different reaction volumes were also assayed by laser light scattering and 
transmission electron microscopy.   
 
App.2 Materials and methods 
App.2.1 ARA induced tau polymerization 
Two micromolar tau protein (wild type or cys-less mutant tau (htau40C291/322A)) 
was incubated in polymerization reaction buffer (10 mM HEPES pH 7.6, 100 mM 
NaCl, 0.1 mM EDTA and 5 mM DTT) in the presence of 75 µM ARA (in ethanol, 
final concentration was 3.75%) for 20 hrs (101).  MgCl2 and CaCl2 at a low (0.3 mM) 
or high (3 mM) concentration with or without 2 mM ATP were added to the reactions 
when indicated in the results section.  The total volume of the polymerization reaction 
was 200 µl unless separately indicated. 
 
App.2.2 Carboxylate-conjugated polystyrene microspheres induced tau 
polymerization 
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  Tau protein at final concentration of 2 µM was incubated in polymerization 
buffer  (10 mM HEPES pH 7.6, 100 mM NaCl, 0.1 mM EDTA and 5 mM DTT) in 
the presence of carboxylate-conjugated polystyrene microspheres (final 
concentrations were 0-6056 pM) at 37 ºC with constant rotation for 20 hr (204).   
 
App.2.3 Right angle laser light scattering 
Tau polymerization reactions after 20 hr incubation were transferred into 5 х 5 
mm optical glass fluorometer cuvettes  (Starna Cells, Atascadero, CA) and 
illuminated with a 5 mW solid state laser (λ = 475 nm, B & W Tek, Inc., Newark, 
DE).  Images were captured at 90º to the incident light using a SONY XC-ST270 
digital camera.  Resulting images were imported into Adobe Photoshop 7.0.1 and the 
intensity of the scattered light was measured by the histogram function of Adobe 
Photoshop (101).  The images were captured at four different apertures (f5.6, f8, f11 
and f16) and normalized to the intensity corresponding to f5.6 or f8. 
 
App.2.4 Transmission electron microscopy 
Tau polymerization reactions after 20 hr incubation were diluted 10-fold with 
polymerization buffer and then fixed with glutaraldehyde (final concentration was 2%) 
for 5 min.  Ten microliters of fixed reactions were placed on formvar-carbon coated 
grids for 1 min, washed with water, blotted, washed with 2% uranyl acetate, blotted 
again, stain with 2% uranyl acetate for 1 min, and then blotted dry.  Grids were 
viewed with a JEOL 1200 EXII electron microscope and digital images were captured 
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with the MegaViewII imaging system (Soft Imaging System, GmbH Münster, 
Germany).  The captured images were imported into Optimas analytical imaging 
software (Media Cybernetics, Sliver Spring, MD).  The number of filaments and the 
average filament length were determined from the digital electron micrographs.  The 
filament lengths measured by Optimas were exported to Prism GraphPad (San Diego) 
and sorted into 50 nm bins, with the center of the first bin at 25 nm.  At least four 
images were analyzed for each reaction condition.  The average length of filaments 
was multiplied by the total number of filaments to obtain the total filament mass for 
each field. 
 
App.2.5 Critical micelle concentration (CMC) determined by laser light scattering 
ARA ranging from 25 µM to 150 µM final concentrations was diluted into 
polymerization buffer in the presence or absence of 2 µM htau40I277/308P mutant tau 
and scattered light was measured as described above.  MgCl2 and CaCl2 at a low (0.3 
mM) or high (3 mM) concentration with or without 2 mM ATP were added to the 
reaction as indicated in the results section.  CMC was determined from abscissa 
intercepts with least squares linear regression (204).  Only data points in the linear 
portion of the curve were used for the calculation. 
 
App.2.6 Critical micelle concentration (CMC) determined by NPN fluorescence 
ARA ranging from 25 µM to 150 µM final concentrations was diluted into 
polymerization buffer containing NPN (final concentration was 10 µM) in the 
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presence or absence of 2 µM wild type tau or htau40I277/308P mutant tau.  The samples 
were incubated for 20 min at room temperature before taking the fluorescence 
readings.  The resulting fluorescence was measured at λex of 346 nm and λem of 420 
nm in a 96-well plate format in a Cary Eclipse fluorescence spectrophotometer 
(Varian Analytical Instruments, Walnut Creek, CA) (204, 243).  MgCl2 and CaCl2 at 
a low (0.3 mM) or high (3 mM) concentration with or without 2 mM ATP were added 
to the reaction when indicated in the results section.  CMC was estimated from 
abscissa intercepts with least squares linear regression (243).  Only data points in the 
linear portion of the curve were used for the calculation. 
 
App.3 Results 
App.3.1 CMC determined by LLS and NPN 
Because the molecular nature of arachidonic acid (ARA) depends on the 
solvent, the critical micelle concentration (CMC) of ARA in polymerization buffer 
(10 mM HEPES pH 7.6, 100 mM NaCl, 0.1 mM EDTA and 5 mM DTT) in the 
absence of tau was determined first with laser light scattering (LLS) and N-phenyl-1-
naphthylamine (NPN) fluorescence.  The CMC of ARA in polymerization buffer was 
assayed individually by these two methods (Figure app.1).  The CMC value equals 
the x-axis intercept of the data fit by least squares linear regression.  The CMCs 
determined by LLS and NPN were 54 ± 3 µM and 55 ± 15 µM, respectively.  To alter 
the micelle formation, the divalent cations were added to the solution and the reduced 











































Figure app.1. Critical micelle concentration (CMC) determination.  ARA at 
concentrations varying from 25 µM to 150 µM was diluted in polymerization buffer and then 
assayed by laser light scattering (LLS, ●, left axis) and NPN fluorescence (NPN, ○, right 
axis).  The data were fit by linear regression using Prism GraphPad Software (San Diego, 
CA).  The solid line represents the best fit to linear regression for LLS and the dotted line 
represents the best fit for NPN fluorescence.  CMC was estimated from abscissa intercepts of 









exception observed at 0.3 mM MgCl2 (Table app.1).  Because filaments with different 
morphology were observed in the concurrent phosphorylation and polymerization 
reactions (105), the CMC value under this condition (in the presence of 3 mM MgCl2 
and 2 mM ATP) was also determined by LLS and NPN fluorescence.  The CMC 
values were close to the values in the presence of 3 mM MgCl2 when assayed by both 
LLS and NPN. 
Because the CMC of ARA has been shown to be depressed by tau in solution 
(204), we measured the CMC of ARA in polymerization buffer in the presence of tau 
by NPN fluorescence (Figure app. 2A).  The CMC of ARA was reduced to 9.0 ± 3.3 
µM by the addition of wild type tau (Table app.1), which is close to a previously 
published report (204).  The assembly incompetent tau mutant (htau40I277/308P) was 
also included as a control and a similar CMC value was observed in the presence of 
htau40I277/308P (Figure app.2A).  The CMC values of ARA in the presence of different 
concentrations of divalent cations and 2 µM tau were also measured by NPN 
fluorescence (Table app.1).  In general, the CMC values were further depressed by 
the addition of wild type tau and htau40I277/308P mutant tau in addition to the 
depression caused by divalent cations.  Wild type tau usually had a larger effect than 
htau40I277/308P mutant tau (Table app. 1).  The significant reduction resulting from the 
addition of wild type tau and/or htau40I277/308P mutant tau was observed under all 
conditions with the lone exception observed in the presence of 3 mM MgCl2.  Under 
this condition, wild type tau further reduced the CMC value of ARA compared with 
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the CMC value in the absence of wild type tau.  However, htau40I277/308P mutant tau 
did not have the similar depression effect as wild type tau (Table app.1).   
The CMCs of ARA in the presence of wild type tau and htau40I277/308P mutant 
tau with or without divalent cations were also determined by LLS.  Surprisingly, the 
CMC values were drastically different from those determined by NPN fluorescence 
(Table app.1).  Because the scattering of tau filaments formed from wild type tau 
interfered with the scattering from ARA micelles, only the CMC values in the 
presence of htau40I277/308P mutant tau could be determined by LLS.  Instead of 
decreasing, the addition of htau40I277/308P mutant tau increased the CMC values about 
2-fold (Table app.1).  The increase of CMC resulting from the addition of 
htau40I277/308P mutant tau was also observed in the presence of 0.3 mM MgCl2 and 0.3 
mM CaCl2 (Table app.1).  In the presence of 3 mM MgCl2, the CMC value is about 
the same with or without htau40I277/308P mutant tau.  However, the depression effect of 
htau40I277/308P mutant tau on the CMC value was observed in the presence of 3 mM 
MgCl2 + 2 mM ATP and 3 mM CaCl2 (Table app.1).  The results suggest that ATP 
could also induce the micelle formation in solution in the presence of htau40I277/308P 
mutant tau and CaCl2 had a larger effect than MgCl2 in the aspect of inducing micelle 
formation.  In addition, by comparing the CMC values in the presence and the 
absence of htau40I277/308P mutant tau measured by laser light scattering, it appears that 
tau can increase the CMC of ARA even in the presence of low concentrations of 
divalent cations, but it cannot overcome the enhanced micelle formation at high 
























































Figure app.2.  Tau protein reduces the critical micelle concentration of ARA.  A) ARA 
at concentrations varying from 25 µM to 150 µM was diluted in the absence (ARA,●) or the 
presence of 2 µM wild type tau protein (ARA+Wt, □) or assembly incompetent mutant tau 
(ARA+AI, ○) in polymerization buffer at room temperature and then assayed by NPN 
fluorescence.  B)  ARA at concentrations varying from 25 µM to 150 µM was diluted in the 
absence (ARA,●) or the presence of 2 µM assembly incompetent mutant tau (ARA+AI, ○) in 
polymerization buffer at room temperature and then assayed by LLS.  Since the scattering 
from tau filaments interferes with the scattering from the micelles, the LLS readings in the 
presence of wild type tau were not shown in panel B.  The data were fit using linear 
regression and only data points in the linear portion of the curves were included for the 
calculation.  The solid lines represent the best fit of the selected data points to a linear 
regression.  The dotted lines link the data points that are out of the linear range and were not 
included in the linear regression analysis.  CMCs were estimated from abscissa intercepts of 











Table app.1. Arachidonic acid CMC values determined under different buffer 
conditions at room temperature 
CMC (µM)  
conditions LLS NPN 
 no tau AI tau no tau AI tau wt tau 
ARA  54.3 ± 3.1 98.3 ± 0.2 55.3 ± 15.1 12.7 ± 6.8 9.0 ± 3.3 
ARA + 0.3mM MgCl2 53.9 ± 8.1 93.3 ± 12.9 46.8 ± 11.6 13.5 ± 1.3 8.68 ± 2.3 
ARA + 3mM MgCl2 28.7 ± 3.5 28.4 ± 4.0 13.0 ± 14.4 14.6 ± 3.9 10.7 ± 2.0 
ARA + 3mM MgCl2 + 2mM ATP 28.9 ± 1.1 11.0 ± 2.8 13.0 ± 3.5 4.5 ± 4.9 2.95 ± 1.9 
ARA+ 0.3mM CaCl2 30.5 ± 0.4 50.2 ± 3.5 17.8 ± 7.2 14.5 ± 1.5 6.92 ± 0.9 
ARA + 3mM CaCl2 12.8 ± 0.6 8.2 ± 1.6 13.4 ± 7.0 12.4 ± 2.4 1.09 ± 1.4 
 
Data are presented as average ± s.d. (n ≥ 3). 
LLS, laser light scattering; 
NPN, N-phenyl-1-naphthylamine; 
Wt, wild type tau; 











The difference in results between NPN fluorescence and LLS may due to the 
direct interaction of NPN with tau in the presence of ARA.  NPN is known to bind to 
certain classes of proteins that have high affinities for aldehydes and fatty acids (242), 
therefore the direct binding between tau and NPN in the presence of ARA is possible.  
The other possible explanation for this difference is that the size of some micelles 
may be too small to be detected by LLS.  Therefore, the micelle formation could be 
underestimated by LLS.  If this is the case, more but smaller micelles could form in 
the presence of tau protein.  The addition of divalent cations at high concentrations 
can overcome this effect and induce the formation of more and larger ARA micelles.  
 
App.3.2 Tau filaments have difference morphologies with different ARA status 
To determine whether there are morphological differences in tau filaments 
under conditions of different micelle formation as determined by LLS, 
polymerization of 2 µM wild type tau was induced by 75 µM ARA in different 
conditions.  These reactions were viewed by TEM and the representative images from 
each condition are shown in Figure 3.  In the presence of ARA alone and ARA + 0.3 
mM MgCl2, ARA presented as free ARA or small micelles (smaller than the low 
limitation detectable for LLS) and filament formation was observed (Figure app.3A 
and app.3C).  As shown in Figure 3B and 3D, many small filaments with length 
shorter than 0.25 µm were observed under these conditions.  The average filament 
length was approximately equal under the conditions with or without 0.3 mM MgCl2 













































Figure app.3. The length distribution of tau filaments changes with different ARA 
micelle formation.  Polymerization reactions with 2 µM wild type tau and 75 µM ARA in 
the presence of different concentrations of MgCl2, CaCl2 and ATP were incubated at room 
temperature for 20 hr.  The resulting polymerizations were viewed by TEM and the 
representative electron micrographs taken at 20,000 х are shown.   A) ARA only; C) 0.3 
mM MgCl2; E) 0.3 mM CaCl2; G) 3 mM MgCl2; I) 3 mM MgCl2 + 2 mM ATP; K) 3 
mM CaCl2.  The average mass distribution are shown for each of these condition and 
are plotted as the sum of lengths of the filaments in that bin (y-axis) versus the center 






































































































































Figure app.4. The morphology of tau filaments changes according to different ARA 
micelle formation.  Tau polymerization reactions with 2µM wild type tau and 75µM ARA in 
the presence or absence of divalent cations (MgCl2 or CaCl2) and ATP were incubated at 
room temperature for 20 hr and viewed with electron microscopy.  A) The average filament 
length, B) the average number of filaments per field and C) the “total mass” or the sum total 
length of filaments per field was determined from at least 4 fields.  All data are presented as 
average ± s.d.. 
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filament mass was higher in the presence of 0.3 mM MgCl2 (Figure app.4B and 
app.4C), but none of these increases were significant.   
In the presence of 0.3 mM CaCl2, the CMC values determined by LLS and 
NPN fluorescence were both lower than 75 µM.  The CMC value suggested that 
under the polymerization condition with 75µM ARA + 2 µM tau + 0.3 mM CaCl2, 
the ARA micelles detectable by LLS were formed.  There was a significant increase 
in the number of the filaments longer than 1.0 µm (Figure app.3E and app.3F) (p < 
0.05), and the average length of filament per field was significantly greater than those 
formed in the absence of LLS detectable ARA micelles (Figure app.4A).  The number 
and total mass of filaments per field were slightly decreased compared with these 
formed in the absence of LLS detectable ARA micelles and none of those changes 
was significant (Figure app.4B and app.4C). 
With the addition of 3 mM MgCl2 and 2 µM wild type tau, more LLS 
detectable micelles were expected to form as suggested by CMC value determined by 
LLS.  Under this condition, filaments were observed, and some of the filaments 
seemed to originate from a common point (Figure app.3G).  The length distribution of 
the filaments was also changed with the addition of 3 mM MgCl2, and the majority of 
filaments were shorter than 50 nm in length (Figure app.3H).  At the same time, some 
very long filaments (longer than 2.0 µM) were only observed under this condition 
(Figure app.3H).  However, the overall filament length, number of filaments and 
filament mass were similar to those formed in the absence of LLS detectable ARA 
micelles (Figure app.4).  According to the CMC determined by LLS and NPN 
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fluorescence, the micelle formation of ARA was further increased by the combination 
of 3 mM MgCl2 and 2 mM ATP (Table app.1).  Under this condition, very few 
filaments were formed, and some of these filaments seemed to originate from a 
common site, similarly to those observed in the presence of 3 mM MgCl2 (Figure 
app.3I and app.3J).  Although the average filament length was significantly greater 
than that of the filaments induced by ARA alone, the decreased number of filaments 
resulted in an overall decrease of the total filament mass (Figure app.4). 
The greatest amount of micelle formation should be observed in the presence of 3 
mM CaCl2 according to the CMC values (Table app.1).  Under this condition, no 
filament formation was observed (Figure app.3K, app.3L and Figure app.4). 
 
App.3.3 Free ARA or small ARA micelles are more efficacious in inducing tau 
polymerization.  
Carboxylate-conjugated polystyrene microspheres are microspheres coated 
with COOH- groups and can mimic the negatively charged surface of ARA micelles 
(239).  The anionic surface of the carboxylate-conjugated polystyrene microspheres 
promotes the assembly-competent conformation of tau through simple adsorption and 
this potency directly depends on the anionic charge density of the surface of 
microspheres (239).  Most of the filaments were microsphere associated and appeared 
to grow out of the surface of the microsphere when viewed at 100,000-fold 
magnification using TEM (239).  To compare the polymerization reaction induced by 
ARA with the polymerization induced by micelle-like negatively charged 
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microspheres, carboxylate-conjugated polystyrene microspheres at concentrations 
varying from 505 pM to 6056 pM were used to induce tau polymerization.  Low 
amounts of filaments were observed at the lowest microspheres concentration (505 
pM) in the form of single short filaments emanating from single beads (Figure app.5A, 
app.5J and Figure app.6).  With the increase of microsphere concentration, the 
number of filaments and total filament mass increased to a maximum, and then 
decreased in a biphasic fashion (Figure app.5).  At low microsphere concentrations 
(505 pM and 1009 pM), at most two filaments were observed to emanate from the 
surface of each microsphere (Figure app.5 and Figure app.6).  When the microsphere 
concentration reached 2053 pM, some of microspheres served as the nucleation center 
for polymerization and several filaments were observed to emanate from the surface 
of a single microsphere (Figure app.5 and app.6C).  This phenomenon is similar to 
that which we observed in the polymerization reaction with increasing ARA micelle 
concentrations (Figure app.3E, app.3G and app.3I).  Also similar to ARA induction of 
tau polymerization was the complete diminution of tau polymerization at the highest 
concentration of carboxylate-conjugated polystyrene microspheres concentration 
(Figure app.5G – J and Figure app.6).   To compare the efficacy of ARA and 
microspheres in inducing tau polymerization, the maximum amount of filaments in 
each condition were compared.  The maximum amount of polymerization for ARA 
and microspheres induction was reached under the condition of 0.3 mM CaCl2 + 































































































Figure app.5. Carboxylate-conjugated polystyrene microspheres induce tau 
polymerization.  Two micromolar tau protein was incubated with carboxylate-conjugated 
polystyrene microspheres at concentrations varying from 505 pM to 6056 pM at 37ºC for 20 
hr with constant rotation and viewed with TEM at 20,000х.  The representative images at 
each concentration were shown: A) 505 pM; B) 1009 pM; C) 1514 pM; D) 2019 pM; E) 2503 
pM; F) 3028 pM; G) 6056 pM.  The average filament length (H), the number of filaments (I) 
and “total mass” or the sum total length of filaments (J) from 9 micrographs under each 





























































































































































Figure app.6. Concentration of carboxylate-conjugated polystyrene microspheres 
changes the number of filaments emanating from a single bead.  Carboxylate-conjugated 
polystyrene microspheres at concentrations varying from 505 – 6056 pM were incubated with 
2 µM wild type tau at 37 ºC for 20 hr with constant rotation and reactions were viewed with 
electron microscopy.  The average number of beads with A) one, B) two, and C) three and 
above filaments emanating from its surface was calculated from 9 micrographs at each 
concentration and plotted against the concentration of carboxylate-conjugated polystyrene 
















Figure app.5).  The maximum amount of polymerization induced by ARA was about 
5-fold higher than the maximum amount induced by carboxylate-conjugated 
polystyrene microspheres (Figure app.4C and app.5J).  According to the CMC values 
determined by LLS and NPN fluorescence, both large micelles and free ARA (and/or 
small micelles) were present in the presence of 0.3 mM CaCl2.  The higher value of 
filament mass, compared to anionic microspheres induced polymerization reaction, 
may due to the induction of free ARA or small micelles.  The result also suggested 
that small micelles and/or free ARA had higher potency in inducing tau 
polymerization compared with large micelles.  This is in agreement with the 
previously reported dependence of the amount of polymerization on the concentration 
of negative charges on the microspheres surface (239). 
 
App.3.4 The surface area : volume ratio of the reaction influences tau polymerization 
and changes the length distribution of tau filaments.  
In vitro results on the effect of pseudophosphorylation on tau polymerization 
from different groups are somehow in conflict (100, 244).  Many factors have been 
shown to change the amount of tau polymerization in vitro (194), such as the inducer 
to ARA ratio and the status of ARA.  The ratio between surface area and reaction 
volume was also found to influence the amount of tau polymerization in vitro.  To 
make the calculation easy, the polymerization reactions were performed in glass 
cuvettes with constant surface area.  By changing the volume of the reactions, the 







































Figure app.7. The surface area : volume ratio changes the amount of tau polymerization.  
The polymerization reactions with 2 µM tau protein and 75 µM ARA inducer in a total 
volume of 200 µl, 400 µl or 600 µl were incubated in optical glass fluorometer cuvettes at 
room temperature for 20 hr.  The surface area : volume ratios are 0.925/mm, 0.8325/mm and 
0.84/mm for 200 µl, 400 µl and 600 µl reactions, respectively.  The amount of polymerization 
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Figure app8. The morphology and the length distribution of tau filaments are affected 
by the surface area : volume ratios.  The polymerization reactions with 2 µM tau protein 
and 75 µM ARA inducer in a total volume of 200 µl, 400 µl or 600 µl were incubated in 
optical glass fluorometer cuvettes at room temperature for 20 hr.  The surface area : volume 
ratios are 0.925/mm, 0.8325/mm and 0.84/mm for 200 µl, 400 µl and 600 µl reactions, 
respectively. The resulting reactions were viewed by TEM.  Six TEM images for each 
reaction were captured and the representative micrographs were shown in panel A-C (200 µl, 
400 µl and 600 µl, respectively).  The total filament mass were determined by using the 
Optimas measuring program and shown in panel D.  The distribution of the filaments was 
shown in panel E and individually colored.  All data are presented as average ± s.d. (n=6). 
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polymerization were observed at the different surface area : volume ratios (Figure 
app.7).  The surface area : volume ratios are 0.925/mm, 0.8325/mm and 0.84/mm for 
200 µl, 400 µl and 600 µl reactions, respectively.  The LLS readings had a biphasic 
dependence on the surface area : volume ratio, with the maximum reading being 
reached at the surface area : volume ratio of 0.8625 mm-1.  The amount of 
polymerization was also assayed by TEM (Figure app.8).  However, the biphasic 
dependence on the surface area : volume ratio was not observed.  Instead, total 
filament mass increased with the decrease in surface area : volume ratio (Figure 
app.8D).  There were more short filaments formed in the reactions with the decrease 
in surface area : volume ratio, and these short filaments were not detectable by LLS 
but by TEM (Figure app.8E).  The presence of these short filaments likely caused the 
difference between LLS and TEM.  In agreement with the presence of more but 
shorter filaments in the reaction with larger final volume, the half time of the 
polymerization reactions were decreased in the reactions with larger final volume 
(Figure app.9C).  By changing the surface area : volume ratio, the oxidative condition 
of the reaction could be changed.  Therefore, we tested the kinetics of the 
polymerization reaction with 2 µM cysless mutant tau at various surface area : 
volume ratio.  The two cysteine residues (Cys291 and Cys322) were replaced with 
alanine in the cys-less mutant tau (htau40C291/322A) and the polymerization of cysless 
mutant tau would not be affected by the oxidative condition through cysteine 
oxidation.  However, similar biphasic dependence of the maximum laser light  
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Figure app.9. The kinetics of tau filaments are affected by the surface area : volume 
ratios.  The polymerization reactions of 2 µM tau (wild type or cysless mutant) and 75 µM 
ARA inducer in a total volume of 200 µl, 400 µl and 600 µl were incubated in optical glass 
fluorometer cuvettes at room temperature for 20 hr.  The surface area : volume ratios are 
0.925/mm, 0.8325/mm and 0.84/mm for 200 µl, 400 µl and 600 µl reactions, respectively.  
The kinetics of the reactions were monitored by LLS at regular intervals.  The amount of 
polymerization was plotted versus time and shown in panel A.  The data were fit to a non-
linear Boltzmann sigmoidal equation and the maximal laser light scattering (LLSmax) and 
half time of the reaction (T1/2) were determined from the equation and plotted in Panel B and 















scattering on the surface area : volume ratio and the decreased half time were 
observed in the cys-less mutant tau (Figure app.9).  This result suggested that the 
changes on the amount of polymerization with the changes of surface area : volume 
ratio was not through changing the oxidation of cysteines in the reaction.  
 
App.4 Discussion 
App.4.1 Comparison between laser light scattering (LLS) and N-phenyl-1-
naphthylamine (NPN) fluorescence in determining the critical micelle concentration 
(CMC) in the presence of tau protein   
The formation of micelles from free fatty acid in solution depends on both the 
structure of the fatty acid and the medium composition (pH, temperature, ionic 
strength) (245).  NPN fluorescence and LLS are two methods currently used to 
determine the critical micelle concentrations (CMCs) of arachidonic acid (ARA).  
The CMC determined by LLS is based on the size difference between large particles 
(micelles) that can scatter light and small particles and/or free ARA that can not 
scatter light.  The CMC determined by NPN comes from the increase in the 
fluorescence intensity and a blue shift on the maximum fluorescence emission after 
NPN molecules partition into the core of micelles (243).  In our buffer system, the 
CMC values determined by NPN fluorescence and LLS are similar in the absence of 
tau protein.  However, in the presence of tau, the CMC value determined by NPN 
fluorescence is significantly lower than that determined by LLS (Table 1).  There are 
two possible explanations for the difference between these two methods.  The first 
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possibility comes from the direct binding between tau and NPN in the presence of 
ARA.  NPN has been shown to bind certain classes of proteins that have high 
affinities for aldehydes and fatty acids (242).  In addition, NPN is structurally similar 
to 8-anilino-1-napthalene sulfonic acid, which is a planar aromatic dye and binds to 
an intermediate in the tau polymerization pathway (246).  The second possibility is 
that micelles formed in the presence of tau are too small to be detected by LLS.  
Because of this technical limitation, it is impossible to differentiate small micelles 
from free ARA.  However, the results from this study suggested that free ARA and/or 
small micelles may induce tau polymerization through a different mechanism than 
large micelles.  This is supported by the observation that the morphologies of tau 
filaments are significantly different in the presence of 0.3 mM CaCl2 and 3 mM 
MgCl2, although the CMC values are similar as determined by NPN fluorescence 
(Table app.1 and Figure app.4).   
 
App.4.2 ARA can induce tau polymerization through two different mechanisms.   
Tau protein has been shown to adopt local beta strand conformation with 
several hydrophobic residues on one face and a relatively polar face on the opposite 
side (reviewed in (65, 247)).  The presence of a positively charged proline rich region 
would prevent the self aggregation of wild type tau (248).  Therefore, polyanionic 
compounds are required for in vitro tau aggregation.  ARA has been hypothesized to 
induce tau polymerization by two mechanisms.  As a monomer, the negative charges 
on ARA can neutralize the positively charged proline rich region and offset the 
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electrostatic repulsion between proline rich regions.  The hydrophobic tail of ARA 
monomer can also interact with the hydrophobic side chains and further facilitate the 
polymerization.  The double effects of ARA monomer on tau polymerization could 
make it a more efficient inducer than ARA micelle.  As large micelles, ARA may 
induce tau polymerization by binding to tau and inducing beta strand conformation on 
the negatively charged micelle surface.  Tau concentrated on the micelle surface 
produces a localized high concentration of tau protein and therefore overcomes the 
energy barriers for the nucleation (249).  It is not clear whether small micelles exist.  
If they exist, small micelles might work through a similar mechanism as ARA 
monomer but with a different efficiency.  Because the size of small micelles might 
not be large enough to produce a localized high concentration, they could neutralize 
the positive charges in the proline rich region after binding. Therefore, the filaments 
with different morphology than those induced with large micelles should be observed.  
The data from our study provided evidence for both of these two mechanisms.  
The CMC of ARA was about 100 µM in the presence of tau as determined by LLS.  
This suggests at the ARA concentration we used (75 µM), ARA in present as 
monomers or small micelles.  ARA may be present in similar states in the presence of 
0.3 mM MgCl2 because both the CMC value and the polymerization of tau were 
largely unaffected by the addition of low concentrations of MgCl2.  In the presence of 
a low concentration of CaCl2, the CMC value was lower than 75 µM, which 
suggested ARA was in the state of the combination of large micelles and free ARA 
(or small micelles).  The polymerization under this condition was slightly changed.  
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In the presence of a high concentration of MgCl2, a high concentration of MgCl2 plus 
ATP and a high concentration of CaCl2, a drastically increased micelle formation was 
detected by both NPN fluorescence and LLS.  The morphology of filaments also 
changed accordingly.  There were less but longer filaments formed and some of the 
filaments appeared to nucleate from a single center.  These results also suggested that 
large ARA micelles induced tau polymerization with lower efficiency.  The 
polymerization induced by carboxylate-conjugated polystyrene microspheres was 
similar to that induced by large ARA micelles and gave the direct evidence for the 
micelle induction hypothesis.  When the concentration of micelles or carboxylated-
conjugated polystyrene microspheres is too high, localized high concentration of tau 
can no longer be produced, therefore tau polymerization could not be observed under 
these conditions.   
 
App.4.3 The surface area : volume ratio affects tau polymerization. 
In vitro tau polymerization can be affected by many factors, such as the ARA 
to tau ratio (194) and the molecular nature of ARA as shown in this study.  The 
surface area : volume ratio was also found to change the polymerization of tau and 
the morphology of tau filaments.  More but shorter filaments were observed with the 
decrease of surface area : volume ratio (Figure app.8).  Also an increased half time 
was associated with the changes in the tau morphology (Figure app.9).  This change 
was not through changing the oxidation of cysteines in the reaction.  The CMC of 
ARA was not changed with the changes of the surface area : volume ratio as assayed 
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by LLS (data not shown).  However, due to a technical limitation, small micelles can 
not be differentiated from ARA monomers.  It is possible that the ratio between 
micelles (large or small) and ARA monomer was changed although no detectable 
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